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• 1 
G E N E R A L I N T R O D U C T I O N 
Introduction 
The background of this study concerns hypertension as one of the risk factors 
for cardiovascular diseases. Hypertension is frequently detected in patients in 
general practice. The incidence in the Continuous Morbidity Registration (CMR) 
was 4.9 per 1000 patients per year.1 A much larger group is under treatment 
(prevalence in the CMR was 58.9 per 1000 patients per year). The rationale of 
treatment of (a-symptomatic) hypertension has been at the forefront of clinical 
research in the past decades. The results of the many trials are - in the light of 
the high prevalence of hypertension - of importance for general practice. 
Randomised antihypertensive drug trials 
There is a long tradition in research on detection and treatment of hypertension. 
One of the first studies in this field was the Veterans Administration (VA) 
Cooperative Study, which showed, that antihypertensive treatment in men with 
high diastolic blood pressure ( > 115 mmHg) had an impact on morbidity and 
mortality.2 
Since then a number of studies, more or less placebo controlled, have been 
carried out, like a continuation of the VA trial and the Oslo study.3 4 Because 
morbidity and mortality rates in these studies appeared to be small, the evidence 
is not overwhelming.5 The Australian National Blood Pressure study (ANBP), the 
trial of the European Working Party on Hypertension in the Elderly (EWPHE) and 
the trial of the British Medical Research Council on treatment of mild hyper-
tension (MRC) were single blind placebo controlled studies.6 7 8 In these studies 
there was a varying impact on fatal and non-fatal cardiovascular heart disease, 
but no significant influence on total mortality. Nevertheless treatment of hyper-
tension did become the standard practice. The ethical implications of this 
practice were that placebo controlled studies on hypertension no longer were 
acceptable. Later studies have been carried out, which made a comparison 
between 'normal care' and 'special care'. The Hypertension Detection and Fol-
low-up Program (HDFP), in a community-based, randomized controlled trial, com-
pared the effects on five-year mortality of a systematic antihypertensive treat-
ment program (Stepped Care) and referral to community medical therapy 
(Referred Care).9 10 The Multiple Risk Factor Intervention Trial (MRFIT), in a 
randomized, primary prevention trial, determined the effects of a multifactorial 
intervention strategy, including stepped-care treatment for hypertension, on 
mortality from coronary heart disease in high risk, middle-aged men, over 6 to 8 
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years of fol low-up.1112 The HDFP showed a significant decrease of total mortali-
ty and fatal stroke, whereas in the MRFIT the usual care group showed less total 
mortality, fatal and non-fatal stroke, and fatal coronary heart disease compared 
with the special intervention group. 
The Treatment of Mild Hypertension Study (TOHMS), a randomized, double 
blind, placebo-controlled clinical trial compared six antihypertensive 
interventions, together with non-pharmacological advices, for the treatment of 
mild hypertension.13 Drug treatment was more effective in preventing cardio-
vascular and other clinical events, but differences between drug-treatment 
groups were minimal. This study supported the recommendations of the fifth 
Joint National Committee (JNC V) report regarding treatment choices for people 
with mild (systolic: 140-159, diastolic: 90-99 mmHg) hypertension. This fifth 
JNC report stated that because diuretics and ß-blockers are the only classes of 
drugs that have been used in long-term controlled clinical trials and have shown 
to reduce morbidity and mortality, they are recommended as first-choice agents 
unless they are contraindicated or unacceptable, or unless there are special 
indications for other agents.14 
From various reviews of controlled clinical trials of drug treatment for 
hypertension, a decrease of 5-6 mmHg in diastolic blood pressure appears to be 
associated with a significant reduction of 42% (95% CI 33-50%) in fatal and 
non-fatal stroke, and 14% (95% CI 4-22%) reduction in coronary heart 
disease. 1 5 1 β A reduction of total mortality is observed, but this reduction does 
not reach statistical significance. 
Hypertension studies in general practice 
In the Netherlands various studies in general practice have demonstrated that 
screening for hypertension by case-finding is feasible.1 7 1B In other studies 
persons with high risk for cardiovascular diseases have been detected and 
included in intervention-programmes.1 9 2 0 
Since 1976 at the Nijmegen University on the Department of General Practice 
and Social Medicine research has been done in the field of prevention of cardio-
and cerebrovascular diseases. The Nijmegen Intervention Project (NIP) showed 
that detection and treatment of patients with high risk for cardiovascular disease 
was feasible and effective in general practice, provided that there was a 
systematic practice management with surveillance of hypertensive pat ients. 2 1 2 2 
2 3
 In continuation of the NIP a project on detection of cardiovascular risk factors 
in general practice (RIFOH) was carried out. The RIFOH project showed that GPs 
are able to carry out a program in the field of cardiovascular disease if certain 
conditions are met. These conditions were the way in which surgeries are organ­
ized, support of a practice nurse, separate payment for extra work and external 
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practical and administrative support.2* 25 The PreTension project, as a con-
tinuation of NIP and RIFOH, showed that a preventive program for cardiovascular 
disease jointly set up and carried out by GPs and Public Health Services was 
feasible.28 
Based on experiences from the NIP, RIFOH, PreTension project, Oxford Preven-
tion of Stroke-project and the British Family Heart Study, the Huisarts-Assis-
tentie-Preventie-Project (HAPP) has been developed. Results will soon be 
published. The aim of this research project is to improve practice management 
concerning prevention of cardiovascular disease with the assistance of practice 
nurses.27 2a 2S 30 31 32 There have been some projects to detect hypertensive 
patients or high risk persons in cooperation with the general practitioner.33 34 
Based on the results of the NIP a group of general practitioners connected with 
the Nijmegen University developed a semi-automated hypertension monitoring 
system (the Nijmegen HMS).35 In the mean time this monitoring system has been 
evolved in the Nijmegen Monitoring Project (NMP), which besides care for 
hypertension also includes care for diabetes mellitus and recently care for 
asthma and COPD.3" 
High risk strategy 
In the discussion about the prevention of cardiovascular diseases the 
phenomenon of the prevention-paradox plays an important part. This paradox 
concerns the discrepancy between the benefit on morbidity and mortality of on 
the one side the population-based strategy and on the other hand the high-risk 
strategy. In the population-based strategy there is great profit for the population, 
but less for the individual. The high-risk approach gives more advantage for the 
individual, but less for the population. In recent years research involving 
cardiovascular diseases more and more stresses the .detection of high-risk 
patients. This strategy acknowledges the on average small health gains, as 
reported in most intervention studies reviewed above: it concentrates treatment 
in those likely to benefit most. 
Left Ventricular Hypertrophy (LVH) 
An important parameter in patients with high-risk of cardiovascular diseases is 
the presence of organ-damage, particularly left ventricular hypertrophy (LVH). 
LVH is an independent risk-factor in cardiovascular morbidity and mortality in 
hypertensive patients. 37 3e 39 *° 41 42 43 44 45 4e 47 4B 49 50 51 Data from the Framingham 
study show that LVH as evidenced by electrocardiogram (ECG-LVH) was 
associated with a 3-15 fold increase of cardiovascular events, that no other 
single risk factor approaches LVH in potency. The data further indicate that LVH 
is reversible and/or preventable.40 There is little research on the prevalence of 
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LVH in general practice and on the consequence of the presence of LVH for the 
intensity of pharmacotherapy in selected hypertensive patients in general 
practice. 
Quality of life 
Beyond the high risk strategy another important aspect in detection and 
treatment of hypertension concerns the effect of labelling and screening on the 
quality of life of hypertensive patients.6 2 5 3 S 4 Negative influence of an 
antihypertensive treatment on quality of life makes it less attractive in general 
practice and/or to be used in mild and often asymptomatic hypertensive patients. 
Many questionnaires have been developed to evaluate the quality of life in hyper­
tension, with emphasis on potential side effects of drug treatment.5 5 5 6 5 7 S B 5 9 
Treatment with antihypertensive agents could have undesirable side effects and 
could influence compliance of patients. 6 0 6 1 6 2 β 3 β 4 β 5 β 6 Discontinuing drug treat­
ment did lead to a marked improvement in perceived health status.6 7 
Aim of the study 
Systematic monitoring of hypertensive patients in general practice ought to be 
aimed at long-term effects of hypertension and its treatment. 
The aim of this study is to analyze the effect of systematic hypertension 
treatment (special care) on objective and subjective health status of hypertensive 
patients in general practice, with special attention to hypertension treatment in 
hypertensive patients with LVH. It contributes to the high risk strategy of 
hypertension care and explores the effectiveness of supervised long term care. 
THE MAIN A I M OF THIS STUDY IS: 
1. What is the effect of special hypertension care in general practice on time 
course of blood pressure and LVH. 
S U B Q U E S T I O N S R E L A T E D T O T H E M A I N A I M A R E : 
2. What is the effectiveness and feasibility of a computer-assisted hypertension 
monitoring system in general practice. 
3. What is the reproducibility of screening on LVH among hypertensive persons 
in general practice and what are the optimal criteria. 
4. What is the prevalence of LVH in hypertensive patients in general practice. 
5. What is the effect of special hypertension care in general practice on the 
quality of life of hypertensive patients in general practice. 
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General introduction • 
The present study ¡s a controlled intervention study with randomisation on 
practice level. 
General Practices 
I 
Randomisation 
4 i 
CHAPTER 2: 
Hypertension Monitoring System Special Usual 
Care Care 
i I 
Baseline Measurement 
1 i 
CHAPTER 3: 
Reproducibility of left ventricular hypertrophy 
CHAPTER 4: 
Prevalence of left ventricular hypertrophy 
CHAPTER 5: 
Effect of special care on blood 
pressure and left ventricular hypertrophy 
CHAPTER 6: 
Influence of treatment on blood 
pressure and left ventricular hypertrophy 
CHAPTER 7: Effect on quality of life 
Key aspects of the study 
Intervention 
The aim of the Nijmegen Hypertension Monitoring System (HMS) was to give 
GPs insight in their hypertension management and to improve practice 
management on detection, follow-up and treatment of hypertensive patients. 
Participating practices 
In the vicinity of Nijmegen 16 general practices were recruited for this study. 
4 ^ 
Final measurement 
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The participating practices were randomised in two groups: an intervention-
group (Special Care: SC) and a control-group (Usual Care: UC). In the SC-group 
the GPs received support in treatment and follow-up of hypertensive patients by 
means of the HMS, particularly of patients with LVH. The HMS is based on two 
components. A computer at the Department of General Practice/Family Medicine 
is used to register data from each hypertension visit in practice. These data are 
processed into surveys and sent to the SC practices. In addition there are regular 
meetings of the GPs In the SC practices at which the practice surveys are 
discussed. These meetings were intended for discussion on follow-up of 
hypertension control, but in the course of time assumed an audit character. The 
UC-group did not get special support. Once again it Is stated that randomisation 
Is executed on practice level, not on patient level. 
Selection 
By means of systematic analysis of patient files all known and/or treated 
hypertensive patients out of the 16 practices have been selected. The concerned 
patients were detected with hypertension in the years before the study by 
means of case-finding (opportunistic screening in patients who for some reason 
visit their GP), not by means of screening. 
After informed consent the patients were included In the study. 
Measurements 
Of all patients in a baseline and final measurement demographic data, treatment 
data, and data on subjective and objective health status were recorded. The 
subjective health status was registered by means of a questionnaire and the 
objective health status was recorded by means of blood pressure measurement, 
electrocardiogram (ECG), Body Mass Index (BMI), serum cholesterol and smoking 
status. 
Guide to this thesis 
The thesis contains the following topics. 
Hypertension Monitoring System 
In CHAPTER 2 a pilot-study on follow-up and treatment of hypertensive patients in 
15 general practices Is described. These 15 practices are not the same as the 16 
practices in the main study. 
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LVH: Reproducibility 
A problem in the diagnosis of LVH is standardising ECG measurements. Before 
time course of LVH can be described reproducibility of ECG-LVH measurement 
ought to be known. In CHAPTER 3 a reproducibility-analysis is described within 
this study, in which variability of indicators of ECG-LVH are measured at short 
and long term. 
LVH: Prevalence 
The prevalence of LVH assessed by ECG in different studies varies from 5% to 
3 4 % . The variation in these prevalence figures can be explained by diverging 
criteria for LVH in those studies.9 3 9 4 3 β β β 9 
In CHAPTER 4 the prevalence of ECG-LVH of this study is described in relation to 
age, gender, blood pressure, treatment status and duration of hypertension. 
THE OUTCOME 
Time course of LVH 
LVH is the most important predictor of total and fatal coronary heart disease 
(CHD). Regression of LVH is possible. When evidence of LVH disappears, the 
risk on total, cardiovascular and CHD mortality decreases. In CHAPTER 5 the 
effects of special care are presented, particularly on time course of blood 
pressure and LVH. In CHAPTER 6 the influence of antihypertensive treatment on 
blood pressure and LVH is described. 
Time course of quality of life 
CHAPTER 7 describes the effect of hypertension treatment on quality of life in 
relation with some clinical parameters (cardiovascular risk factors, blood 
pressure, comorbidity and LVH). 
In the general discussion (CHAPTER 8) the meaning of this study on hypertension 
care in general practice is discussed. Conclusions and recommendations are 
made. 
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Introduction 
From 1976 - 1979 we carried out a systematic detection and intervention pro-
gramme in six general practices (four study and two control practices) aimed at 
the most important cardiovascular riskfactors. This Nijmegen Intervention Study, 
in which 850 high risk patients were treated for more than one year, proved to 
be practicable and produced similar results in all the study practices. 1 
An evaluation study was introduced five years later, and focussed on the long-
term results in terms of risk factors and the relationship between hypertension 
and practice organisation. This evaluation study showed that it is difficult to 
alter cardiovascular risk factors in the long term, even in high risk individuals. 
We found considerable differences in long-term results between the practices, 
and a positive correlation between these long-term results and factors related to 
practice organisation (management). The results stressed the importance of 
surveillance of high risk persons. 2 
The systematic surveillance of groups at risk as part of practice management is 
not common in Dutch general practice. It requires a specific view at the popula-
tion. The lack of good organisational and administrative structure in Dutch gene-
ral practice is one of the most important factors preventing introduction of such 
a procedure. 
Based on previous research and international experience, a computer-assisted 
hypertension monitoring system (Nijmegen-HMS) was developed and imple-
mented in the practices included in the studies mentioned above. 3 4 5 e 
The aim of the HMS was an improved detection, follow-up and treatment of 
hypertensive patients. This HMS is based on two components. A computer at 
the Department of General Practice/Family Medicine at Nijmegen University regi-
sters data from each hypertension follow-up visit in study practices, processes 
them into surveys, and sends them to the participating practices. Regular mee-
tings of the participating doctors are held at which the practice surveys are di-
scussed. These meetings were initially intended for discussion on procedural 
matters, but in the course of time they increasingly assumed an auditing charac-
ter. 
Aims of the study 
The effectiveness and feasibility of the HMS were investigated in practices 
which were not part of the former studies. We studied 15 practices consisting 
of seven 'special care' practices (SC) and eight 'usual care' practices (UC). The-
se practices recorded their newly detected hypertensives in the two years prece-
ding the start of this experiment. The aims of the study were to investigate the 
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effectiveness of hypertension detection and treatment in practices working with 
the HMS (SC) in comparison with detection in practices with usual care (UC), 
and the effectiveness of hypertension follow-up in both groups. 
Methods 
We studied the application of the HMS during one and a half year in the seven 
SC practices, during which time the eight UC practices supplied their usual care 
for hypertension patients. Special HMS forms were used to record all 8data of 
hypertension detection and treatment in the SC practices. We had no contact 
with the UC practices during the study and all data on the control of hyperten­
sives in these practices were recorded on their standard files. 
Results 
The SC practices and the UC practices did not differ on practice characteristics. 
In the study practices, 395 newly detected hypertensives in the 36 - 55 year 
age group were added to the 1724 already known hypertensives identified by 
means of a search through the patient files. The total hypertensive population of 
2119 persons in the study practices were followed with the help of this monito­
ring system. In the UC group 179 hypertensive patients were newly detected, 
and no further file search for already known hypertensives was carried out. 
Thus, comparisons between the two groups were limited to newly detected 
hypertensives. 
The SC and UC groups were compared in terms of the number of newly detec­
ted hypertensives, blood pressure (BP) level, and the percentage of patients 
under permanent surveillance. 
Newly detected hypertensives 
The prevalence of hypertension in the study practices was 6.7%. During the 
study period, 395 newly detected persons were added, an incidence of 0.7%. 
Comparable figures are not available from the UC practices, because they had 
no systematic hypertension registration. Nor was there a way to trace newly 
detected patients after the study period. 
Blood pressure level 
All check-ups were recorded in the SC group. The diastolic BP target level of 95 
mmHg was achieved in 7 0 % of the already known and the newly detected hy-
- 15 -
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pertensives (n = 395). 
In the 179 hypertensives who were recorded in the UC practices prior to the 
start of this study, and therefore identifiable after the study period, the BP target 
level was reached in 56% (figure 1). By means of a Chi-square test there was a 
significant difference between SC and UC group. 
The percentage of persons under permanent surveillance 
In the study practices 76% of the hypertensive patients were under permanent 
surveillance during the study compared with 45% in the UC practices (figure 1): 
a significant difference. 
Figure 1 Treatment and follow-up results: usual care versus special care. Percentage 
under target level ( < 95 mmHg) and percentage under permanent control. 
Feasibility of the HMS 
Evaluation of the HMS at the end of the study indicated that the introduction of 
such a system is possible without insurmountable problems. While a great deal 
of time was spent in making a survey of all known hypertensive persons at the 
beginning of the study, about thirty minutes a week were required thereafter to 
register hypertension check-ups on special forms. 
The discussions in the regular meetings of the participating doctors influenced 
their management of hypertension follow-up and treatment. The change took 
the form of a more active attitude towards hypertensive patients who might 
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otherwise not have been checked, and patients with permanently high blood 
pressure. 
Discussion 
In view of the results presented here we consider this hypertension monitoring 
system (improved detection, follow-up and treatment of hypertensive patients) 
to be effective and feasible. The components of the system which are 1) insight 
into the results of treatment In individual patients and in the entire hypertension 
population, 2) insight into personal performance, and 3) regular group discus­
sions about the results, were effective in stimulating the general practitioners to 
assume an active attitude towards the management of blood pressure follow-up 
and treatment. This system has now been extended to more Dutch general prac­
tices. We have initiated a research project to study the efficacy of optimal 
hypertension treatment on organ damage (heart and kidney) in general practice. 
If further research proves that compliance of patients and the state of health of 
hypertensive patients is improved, a comparable monitoring system could be 
applied to persons with other chronic diseases requiring long-term treatment 
including diabetics and persons with chronic obstructive lung disease. 
- 1 7 -
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Introduction 
Left ventricular hypertrophy (LVH) on electrocardiogram (ECG) is an important 
predictor of coronary heart disease. 1 2 
Regression of LVH is possible, but before changes in ECG voltage criteria can be 
accepted as evidence for regression one needs to know something about the variabi­
lity of the ECG measurements. Farb and others э found that the coefficient of 
variation for single leads ranged from 18% for R/l to 3 9 % for S/lll. For combined 
voltage criteria (Sokolow-Lyon, Gubner-Ungerleider and Cornell) the coefficient of 
variation was lower, ranging from 19% for Sokolow-Lyon (SL) to 2 5 % for Cornell. 
Reclassification due to variation above and below standard criteria for LVH occurred 
in 3 to 4 % . The data from the study indicate that serial variability of ECG voltage 
combinations is high. 
The WHO reviewed the use of ECG to detect signs of cardiac involvement (in this 
case LVH) in 1962 * and in 1978 5. It is suggested that the SL voltage criterion 
(RV5/RV6 + SV1 > 3.5 mV) for LVH be retained, although its limitations are recog­
nized. 
We report on the results of a study to measure the variability of electrocardiographic 
single lead voltage parameters and (voltage) criteria for left ventricular hypertrophy 
in hypertensive patients in general practice. 
Methods 
By means of case-finding 1803 hypertensive patients from 16 general practices (with 
a total of about 51,000 patients) were selected from the population. 1376 patients 
(76%) gave their consent to participate in a study to measure the effect of optimal 
treatment on the health status of hypertensive patients. From 64 patients, selected 
at random from the hypertensive population, two electrocardiograms were recorded, 
with an interval of two minutes, to measure the minute-to-minute variability. The 
electrodes remained attached to the body during the two minutes in order to avoid 
variation due to different electrode positions. In one practice 77 patients gave their 
consent to have two electrocardiograms recorded, with an interval of about a week 
(6-8 days) in order to measure the day-to-day variability. The electrodes were 
removed after the first registration and replaced for the second ECG a week later, 
without the previous electrode placement being marked. The electrocardiograms 
were made in a standardized way, although it is possible that the electrodes were 
placed in different positions. However, it is plausible that the cardiac status remained 
the same. 
All electrocardiograms were recorded by one well trained person, with one electro­
cardiograph and were measured by computer (Marquette 12 SL ECG Analysis Pro-
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gram). In the Romhilt-Estes point score the terminal negative part of the Ρ amplitude 
in lead V1 and the intrinsicoid deflection in lead V5 or V6 were measured manually. 
All recordings were made in the morning 6 . 
Patients with intraventricular conduction disturbances (WPW pattern and complete 
bundle branch blocks) and myocardial infarction were excluded from this study, as 
it was impossible to evaluate the presence or absence of LVH in these patients. 
The following voltage parameters in single leads were studied for their variability: 
R in the leads I, II, III, aVL, aVF, V5 and V6; S in the leads III, V 1 , V2 and V3; Τ 
in the leads I, II, V1 and V2. 
The criteria for LVH were those most frequently used in the literature: 
1. SOKOLOW-LYON (SL):7 
The sum of the voltages of the S in V1 and the greatest R in V5 or V6 above 3.5 
mV (35 mm). 
2. ROMHILT-ESTES POINT SCORE (RE): β points 
amplitude R or S in lead I, II or III > 20 mm, or 
S in lead V1 or V2 > 30 mm, or 3 
R in lead V5 or V6 > 30 mm. 
terminal negative part of Ρ in lead V1 > 1 mm and > 0.04 sec. 3 
ST-T vector opposite to QRS vector 3 
in case of use of digitalis 1 
QRS-axis > -30 degrees 2 
QRS-duration > 0.09 sec. 1 
Intrinsicoid deflection > 0.05 sec. in lead V5 or V6 1 
The ECG diagnosis of LVH on the basis of this point score is under discussion; it 
is sometimes based on 4 points (RE4) and sometimes on 5 points (RE5). 
In our study we have used both criteria. 
3. CORNELL VOLTAGE CRITERIA (CC): 9 · 1 0 
R/aVL + S/V3: for men > 2.8 mV (28 mm) 
for women > 2.0 mV (20 mm) 
4. GUBNER-UNGERLEIDER (GU): 1 1 
R/l + S/lll > 2.5 mV (25 mm) 
5. MITTAL RATIO (MR): 1 2 
T/l : R/l < 2 0 % 
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6. MINNESOTA CODE ( M C ) : 1 3 1 4 
The following criteria from the MC were used: 
High QRS-voltages without ST-T changes 
(MC 3 . 1 , 3.3 without 4.1-4.3 or 5.1-5.3) 
High QRS-voltages with ST-T changes 
(MC 3 . 1 , 3.3 with 4.1-4.3 or 5.1-5.3) 
Statistical methods 
Both in the minute-to-minute group (M-group) and in the day-to-day group (D-group) 
the variability of the voltage parameters in single leads was calculated as 1 SD of 
the difference between paired measurements, divided by the average mean value 
(coefficient of variation). 
Because of a possible influence of gender and obesity on the variability, coefficients 
of variation were computed for men and women with a Body Mass Index (BMI) < 
27 kg/m2 and > 27 kg/m2. 
The variability of the voltage criteria for LVH was expressed as a coefficient of 
variation for voltage combinations (SL, CC and GU) and as a percentage of 
reclassification between the two paired measurements because of voltage variation 
above and below fixed voltage criteria for LVH. The reclassification percentage is 
defined as the number of patients with regression of LVH plus the number of 
patients with progression of LVH, divided by the total number of patients. 
The variability of the voltage criteria was also expressed in a coefficient of 
agreement (kappa 1 5 ) . The kappa was introduced as a coefficient of agreement 
between the assignments on a nominal scale of two or more raters. This index 
contains a correction for the amount of agreement that is expected by chance. The 
kappa ranges between 0 (no agreement) and 1 (100% agreement). A kappa > 0.65 
indicates a good diagnostic reliability. 
Given a set of variables, factor analytic techniques 1 β enable one to see whether 
some underlying pattern of relationship exists. In our study we used this technique 
to investigate the relationship between the scores on several voltage criteria for LVH. 
Our hypothesis was that all sets of criteria will load on one underlying factor, viz. 
LVH. Variables scoring > 0.40 on a factor are a part of that factor. 
Results 
The M-group and the D-group did not differ significantly with regard to gender, age, 
diastolic blood pressure (DBP), systolic blood pressure (SBP), BMI ortotal cholesterol 
(table 1). 
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Table 1 General characteristics of the minute-to-minute group (M) and the day-to-day group 
(D). Mean +. SD are given 
M (n=64) D (n=77) 
Gender (% men) 
Age (yrs) 
DBP (mm Hg) 
SBP (mm Hg) 
Body Mass Index (kg/m2) 
Total Cholesterol (mmol/L) 
For all voltage parameters the mean coefficient of variation in the M-group was 
8.9% and in the D-group 21.3% {table 2). 
Table 2 Coefficients of variation of single lead voltage parameters on ECG in the minute-to-
minute group (M; n=64) and the day-to-day group (D; n=77) 
Voltage parameter M D 
and lead (%) (%) 
RinI 43 92 
R in II 4.5 9.8 
R in III 16.3 29.4 
R in aVL 6.9 14.7 
R in aVF 8.0 19.0 
R in V5 4.4 13.8 
R in V6 6.2 13.6 
S in III 11.2 35.4 
S in VI 4.2 14.3 
S in V2 4.8 13.3 
S in V3 7.9 14.4 
Τ in I 16.5 37.5 
Τ in II 14.0 31.1 
Τ in VI 17.8 42.2 
Τ in V2 6.7 22.0 
MEAN 8.9 21.3 
In the M-group R/l, R/ll, R/V5, S/V1 and S/V2 had coefficients of variation < 5%. 
Those of R/aVL, R/aVF, R/V6, S/V3 and T/V2 were between 5 and 10%, while the 
coefficients of variation of R/lll, S/lll and all the T-amplitudes (with exception of 
T/V2) were > 10%. 
In the D-group R/l and R/ll had coefficients of variation < 10%. Those of R/lll, S/lll 
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and the T-amplitudes were > 2 0 % . It might be supposed that the coefficients of 
variation in obese people would be greater than those in lean people. This was not 
found in our study. In the D-group the mean coefficient of variation of the 15 voltage 
parameters in persons with a BMI < 27 kg/m2 did not differ significantly from that 
in persons with a BMI > 27 kg/m2 (21.2% versus 21.5%). There was, however, 
a significant difference between men and women (19.5% versus 23.4%). The mean 
coefficient of variation of voltage parameters from limb leads did not differ 
significantly from that of precordial leads. The coefficients of variation for voltage 
combinations intheM-group was 3.1 %, 5.7% and 4 . 6 % for respectively SL, GUand 
CC. In the D-group these coefficients were higher: respectivily 10.0%, 13.7% and 
10.3% (table 3). 
Table 3 Coefficients of variation of voltage combinations in the тіпше-to-minute group 
(M; n=64) and the day-to-day group (D; n=77). 
Voltage combination M (%) D (%) 
Sokolow-Lyon 3.1 10.0 
Gubner-Ungerleider 5.7 13.7 
Cornell 4.6 10.3 
Table 4 Reproducibility of the diagnosis ofLVHin the minute-to-minute group (M; n=64) 
and the day-to-day group (D; n=77). Table shows percentages of reclassification and 
kappa values. 
M D 
Diagnosis of LVH 
according to 
Sokolow-Lyon 
Mittal Ratio 
Gubner-Ungerleider 
Cornell 
. for men 
. for women 
. for both sexes 
Romhilt-Estes 
. on 4 points 
. on 5 points 
Minnesota code 
. high QRS-voltages 
. high QRS-voltages 
reclassi f. 
(%) 
5 
5 
5 
0 
0 
0 
0 
2 
7 
2 
kappa 
value 
0.89 
0.89 
0.83 
1.00 
1.00 
1.00 
1.00 
0.90 
0.84 
0.93 
reclassif. 
(%) 
10 
16 
0 
0 
11 
5 
8 
0 
17 
4 
kappa 
value 
0.63 
0.69 
1.00 
1.00 
0.70 
0.77 
0.36 
1.00 
0.59 
0.55 
with repolarization disturbances 
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The reclassification percentage for LVH {table 4) using SL criteria in the M-group 
was 5.3% versus 10.4% in the D-group, with kappas of 0.89 and 0.63. For RE4 
these percentages were, respectively, 0 and 7.8%, with kappas of 1.0 and 0.36, 
while for RE5 the reclassification percentages were 1.8 and 0%, with kappas of 
0.90 and 1.0. 
The Cornell criteria (CC) are gender specific. For men the reclassification percentages 
in both groups (M and D-group) were 0%, with kappas of 1.0. Those for women 
were, respectively, 0 and 1 1 . 1 % , with kappas of 1.0 and 0.70. In men and women 
together the reclassification percentage in the M-group was 0, with a kappa of 1.0, 
while that in the D-group was 5.2%, with a kappa of 0.77. GU had reclassification 
percentages of 5.3 and 0, with kappas of 0.83 and 1.0 in the respective groups. 
MR had 5.3 and 15.6% reclassification, with kappas of 0.89 and 0.69. When we 
used the Minnesota Code to diagnose LVH, MC with only high QRS-voltages had 
7.0 and 16.9% reclassification, with kappas of 0.84 and 0.59, while MC with 
repolarization abnormalities (ST-Tchanges) had 1.8 and 3.9% reclassification in the 
respective groups, with kappas of 0.93 and 0.55. 
In a factor analysis the Romhilt-Estes criteria, the Sokolow-Lyon criteria and the 
Minnesota code scored on one factor (factor I: Eigenvalue 2.33, explained variance 
33%) while the Cornell and Gubner-Ungerleider scored on a different factor (factor 
II: Eigenvalue 1.48, explained variance 21%). The Mittal ratio did not show 
agreement with the other sets of criteria (table 5). 
Table 5 Factor scores of criteria for LVH. Given are factorscores, Eigenvalue and 
explained variance. 
Factor II 
(MÍ6 
0.80 
0.36 
-0.22 
-0.24 
-0.24 
0.33 
Eigenvalue factor I: 2.33 
Eigenvalue factor II: 1.48 
Explained variance of factor I: 33% 
Explained variance of factor II: 21% 
Criteria for LVH 
Cornell 
Gubner-Ungerleider 
Mittal-ratio 
Romhilt-Estes (4) 
Romhilt-Estes (5) 
Sokolow-Lyon 
Minnesota code voltage criteria 
Facti 
0.26 
0.03 
0.32 
0.80 
0.73 
0.74 
0.67 
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Discussion 
In our study the coefficient of variation of the 15 voltage parameters in the D-group 
ranged from 9 to 4 2 % . The coefficient of variation for voltage combinations ranged 
from 10 to 14%. In the study of Farb 3 the coefficient of variation for single leads 
was found to range from 18% to 3 9 % and for voltage combinations from 19 to 
2 5 % . However, our population consisted of hypertensive patients in general 
practice, while Farb studied medical and surgical patients in hospital. 
The difference in variability of the voltage parameters between the M-group and the 
D-group can be explained by the most important factor influencing the ECG 
measurement: the position of the electrodes. In the M-group the electrodes remained 
on the body, while in the D-group the electrodes might have had a different position. 
A remarkable finding in this study is the great variability in lead III and in the T-
amplitudes. It is debatable whether it is useful to measure these parameters if such 
great variabilities occur. If we leave out lead III and the T-amplitudes, the variability 
coefficient is 5.7% in the M-group and 13.6% in the D-group. 
The results with regard to the reliability of voltage parameters allow the following 
conclusions to be drawn: 
1. The differences in variability between the minute-to-minute group and the day-
to-day group are clear and considerable. The follow-up of LVH in hypertensive 
persons has to be considered with the restrictions found in the data of the day-
to-day variability. 
2. R-amplitudes have good coefficients of variation with the exception of lead III. 
R-amplitudes in leads I and II are very stable, contrary to that in lead aVF. 
3. S-amplitudes have acceptable coefficients of variation, with the exception of 
that in lead III. 
4. The variability of R-amplitudes and S-amplitudes in lead III and T-amplitudes in 
leads I, II, V1 and V2 is very high and we therefore advise not to use these 
voltage parameters in the follow-up of LVH in hypertensive persons in general 
practice. 
On the basis of our study we cannot compute the sensitivity or specificity of the 
voltage criteria used. The prevalence of LVH in our population is not known, because 
an echocardiogram has not been made. Although the use of the ECG to diagnose 
LVH has its limitations 1 7, the ECG for detection of LVH in hypertension, especially 
in large population studies, is not as unreliable as some may think 1S. The sensitivity 
of ECG criteria for LVH has a range from 15% to 5 7 % and the specificity, with the 
echocardiogram as a 'golden standard', ranges from 8 6 % to 9 3 % . The 
echocardiogram, however, has a limited sensitivity (57%) for LVH when mild left 
ventricular hypertrophy is concerned э. 
Some criteria, however, detect more patients with LVH than other criteria. The 
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diagnostic reliability of voltage criteria for LVH is also dependent on the 
reclassification percentage of voltage criteria. Depending on the voltage criteria used 
the reclassification percentages ranged from 0 to 17%. In our study in the D-group 
Gubner-Ungerleider and Cornell Criteria for men and the Romhilt-Estes score on 5 
points showed no reclassification, but these criteria detected fewer patients with 
LVH according to the respective criteria (1.3%, 2.4% and 1.3% respectively) than 
the other criteria and seem to have a poor sensitivity. Mittal-Ratio and the Minnesota 
Code had high reclassification percentages (16 and 17%) and detected a high 
percentage of patients (45.5% and 20.8% respectivily). Cornell Criteria for women 
and Sokolow-Lyon had acceptable reclassification percentages (11 and 10%) and 
seem to have an acceptable sensitivity (tracing 19.4% and 11.7% respectivily). The 
Cornell criteria seem to be more sensitive for women than for men in this study and 
are therefore not useful in practice. 
Our hypothesis was that all criteria would load on one underlying factor (LVH), but 
the Romhilt-Estes score, the Sokolow-Lyon criteria and the Minnesota code obviously 
trace other aspects of LVH than the Cornell criteria and the Gubner-Ungerleider do. 
With regard to the diagnostic reliability of the voltage criteria the following 
conclusions can be drawn: 
1. Diagnostic reclassification of course occurs more often in the day-to-day group 
than in the minute-to-minute group. 
2. The diagnostic reliability of the Mittal Ratio, Gubner-Ungerleider, Cornell Criteria 
and the Romhilt-Estes point score on 5 points is higher (kappa > 0.65) than that 
of the Sokolow-Lyon criteria and the Minnesota Code (0.55 < kappa < 0.65), 
while that of the Romhilt-Estes score on 4 points is low (kappa < 0.45). 
3. Studies which use the Romhilt-Estes score or the Sokolow-Lyon and Minnesota 
criteria to detect ECG-LVH are not comparable with studies which use the 
Cornell and Gubner-Ungerleider criteria. 
The Sokolow-Lyon, Cornell and Gubner-Ungerleider criteria are not as complex to 
use for diagnosing LVH as the Romhilt-Estes point score or Minnesota code in 
general practice. All ECG criteria have a good specificity ( > 90%) 19. 
A great deal of research has been done to develop new criteria for LVH with an 
acceptable sensitivity and reliability, but the diversity of these studies testifies to 
the difficulty of this problem. 
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Introduction 
In recent years many studies have paid attention to the prevalence of left ventricular 
hypertrophy (LVH) as assessed by electrocardiogram (ECG) in hypertensive patients 
and the associated risk of cardiovascular diseases (CVD). This would seem to be 
important because patients with LVH show a considerably higher risk of cardiovascular 
morbidity and mortality than hypertensive patients without LVH. 
In the Framingham Heart Study ECG-LVH was considered to be a predictor of coronary 
morbidity and mortality '. In the Hypertension Detection and Follow-up Program (HDFP) 
the age-adjusted 5-year mortality rate was two to three times higher in the group 
with ECG-LVH than in the group without ECG-LVH 2. The Honolulu Heart Program 
demonstrated that resting ECG abnormalities were independent predictors of both 
total and fatal coronary heart disease (CHD)3. A study from the Glasgow Blood Pressure 
Clinic demonstrated that ECG-LVH, with or without ST-T changes, was an independent 
risk factor for mortality in hypertensive patients 4. 
Both LVH based on voltage criteria alone and LVH based on voltage criteria with ST-T 
changes increase the risk of C H D . 5 β 7 Regression of LVH is possible and many publi­
cations mention such a regression as a result of special care e.g. the Multiple Risk 
Factor Intervention Trial (MRFIT)8, the HDFP9 and the Veterans Administration Trial 
1 0
. The prevalence of ECG-LVH found in several studies ranged from 5 to 3 4 % . This 
range is caused by the fact that several sets of criteria for LVH are being used and 
that the populations in the studies differ. In the HDFP ECG-LVH diagnosed on the 
basis of voltage criteria only, was present in 12.6% of the subjects 1 \ while diagnosis 
requiring the presence of ST-T abnormalities resulted in 3.5% of the subjects having 
ECG-LVH 1 2. Data of the Glasgow Blood Pressure Clinic show that the prevalence 
of ECG-LVH was 3 4 . 5 % in the group with high voltages only and 12.8% in the group 
with ST-T abnormalities 4 . 
In 1988 a study was started in 16 general practices in the vicinity of Nijmegen. The 
aim of this study is to measure the effects of special care on the objective and subjective 
health status of hypertensive patients in general practice. This paper describes the 
prevalence of LVH and the relationship between LVH, age, gender, blood pressure, 
treatment and duration of hypertension. 
Methods 
The study population consisted of 51.000 persons in 16 general practices (22 general 
practitioners) in or near Nijmegen. The participating general practitioners are tutors 
at the Department of General Practice of the University of Nijmegen. They responded 
to a request for participation. In their practices, the patients diagnosed as hypertensive 
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were registered. These hypertensives were detected by means of case-finding, not 
by means of screening. The hypertensive persons have been treated with advice or 
medication longer than two years. An informed consentform was sent to the registered 
patients and if consent was given an appointment was made at the practice. 
The measurements were made in a standardized way and by a practice nurse trained 
especially for this purpose. 
To describe the prevalence of LVH and the relationship between LVH, age, gender, 
bloodpressure, treatment and duration of hypertension the following variables have 
been included: 
1. ELECTROCARDIOGRAM. 
The ECG was made by means of a Marquette electrocardiograph (MAC PC). The 
Marquette 12 SL Analysis Program provides a number matrix of leads and amplitudes. 
The dimension of LVH was measured by computer in accordance with the Minnesota 
Code (MC) 1 3 1 \ 
There are two categories of LVH: LVH based only on voltage criteria (a) and LVH 
based on voltage criteria with repolarization abnormalities (b). 
a. LVH based on high QRS voltages without ST-T abnormalities (MC 3.1, 3.3 without 
4.1 - 4 . 3 or 5.1 - 5.3). 
b. LVH based on high QRS voltages with ST-T abnormalities (MC 3 . 1 , 3.3 with 
4.1 - 4 . 3 or 5.1 - 5.3). 
Patients with intraventricular conduction disturbances (WPW-pattern, complete left 
or right bundle branch block and ventricular block) and myocardial infarction were 
excluded, as it was difficult to evaluate the presence or absence of LVH in these 
patients. 
2. BLOOD PRESSURE. 
Blood pressure was measured two times, at an interval of five minutes, in sitting 
position after five minutes of rest, using a digital, semi-automated sphygmomanometer 
(Yamasu YSE-320). The means of the two systolic blood pressure (SBP) values 
and the two diastolic blood pressure (DBP) values were used for analysis. 
3. TREATMENT 
Type of antihypertensive treatment was recorded. 
4. DURATION OF HYPERTENSION 
The number of years between the measurement and the year of diagnosis was com-
puted. 
A logistic regression1S was used to describe the relationship between the occurrence 
of LVH and bloodpressure, type of treatment and duration of hypertension. The logistic 
regression gives a coherent impact of all variables on the occurence of LVH and 
therefore is more important than the impact of the separate variables. 
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Results 
In the 16 practices, 1803 persons were identified with the diagnosis hypertension. 
An average of 3.5% of the general practice population was regarded as hypertensive 
(ranging from 0.8% to 5.8% per practice). 1373 persons participated in this study 
(response percentage of 76). 
The age-gender distribution of the practice population did not differ significantly from 
that of the Dutch population. In the present study population (N = 1373) 8 0 % was 
older than 50 years. The majority (62%) was female {table 1). 123 patients were 
exluded because of conduction disturbances and/or myocardial infarction. 1250 patients 
remained included in the study. 
Table 1 Characteristics of the study population (n=13 73) and characteristics in patients 
with or without LVH. Table lists mean ± SD 
Characteristic 
Percentage men 
AGE (YEARS) 
Women 
Men 
Total 
BLOOD PRESSURE (mm Hg) 
Systolic 
Diastolic 
Puis rate (beats/min) 
Body Mass Index (kg/m2) 
Total cholesterol (mmol/1) 
Serum creatinine (jimoltl) 
Serum potassium (mmol/1) 
Mean 
Total 
± SD 
(n=1373) 
38 % 
61 
58 
60 
149 
87 
76 
28 
6.5 
94 
3.9 
± 12 
± 12 
± 12 
± 2 1 
± 10 
+ 16 
± 4 
± 1.2 
± 30 
± 0.5 
Mean ± SD 
LVH absent 
(n=988) 
34 % 
60 
56 
59 
147 
87 
± и 
± 12 
± 12 
+ 20 
± io 
Mean ± SD 
LVH present 
(n=262) 
49 % 
64 
59 
61 
157 
88 
± 12 
± 12 
± 12 
± 24 
± 10 
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The prevalence of LVH and the relationship between LVH, age and gender. 
1. ELECTROCARDIOGRAM 
a. 17% of the hypertensive patients showed LVH based on high QRS voltages 
only, without repolarization abnormalities (LVH - rep abn). 
b. LVH based on high QRS voltages with repolarization abnormalities was found 
in 4 % of this population (LVH + rep abn). 
One out of five hypertensive patients had LVH with or without repolarization abnor-
malities (21%). LVH was found relatively more often in men, since LVH without 
repolarization abnormalities was found significantly more frequently in men (p < 0.01 ). 
LVH with repolarization abnormalities was found just as often in both sexes. LVH 
+ rep abn was more frequent in elderly patients (> 65 yrs) both men and women 
(p < 0.01), whereas this did not apply to LVH - rep abn (table 2). 
Table 2 Prevalence of left ventricular hypertrophy (LVH) without and with repolarization 
abnormalities (- and + rep abn) by age and gender. Table lists percentages per age 
category and per gender (n = 1250) 
LVH 
absent 
LVH 
rep abn 
LVH 
+ rep abn 
MEN 
< 50 years 
50-65 years 
> 65 years 
Total 
(n=130) 
(n=202) 
(n=135) 
(n=467) 
78% 
74% 
66% 
72% 
(339) 
22% 
23% 
23% 
23% 
(106) 
0% 
3% 
11% 
5% 
(22) 
WOMEN 
< 50 years 
50-65 years 
> 65 years 
(n=124) 
(n=370) 
(n=289) 
87% 
85% 
79% 
11% 
14% 
15% 
2% 
1% 
Total 83% 
(n=467) (339) 
14% 
(106) 
3% 
(22) 
BOTH SEXES 79% 
(n=1250) (988) 
17% 
(216) (46) 
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The relationship between LVH, blood pressure, treatment and duration of hypertension. 
2. BLOOD PRESSURE. 
At the time of the measurement 6 2 % had a mean DBP < 90 mmHg and 4 % > 105 
mmHg. Mean DBP was 87.0 mmHg (SD 9.9) (table 1 ). Mean SBP was 149.4 mmHg 
(SD 21.1). LVH (with and without rep abn) was found significantly more often in 
the highest SBP category ( > 160 mmHg) and in the highest DBP category ( > 105 
mmHg) (ρ < 0.01) (figures 1 and 2). 
3. TREATMENT 
3 0 % of the hypertensive population did not use antihypertensive medication. This 
part of the population has been treated with advice. 16% of the group used a diuretic 
drug only. 31 % used a ß-blocker with or without another antihypertensive drug. 10% 
received ACE-inhibitors and 13% used other treatment. In the group treated with 
antihypertensive agents with the ability to cause a regression in LVH (ß-blocker and 
ACE-inhibitor) LVH did not occur significantly less often than in the non-treatment 
group. There was no significant difference in BP between patients treated with 
antihypertensive medication and patients without treatment (only advice). 
4. DURATION OF HYPERTENSION. 
18% of the hypertensive patients was known with the diagnosis for less than 5 years, 
3 2 % between 5 and 10 years and 50% was more than 10 years known with 
hypertension. 
The duration of hypertension did not significantly influence the occurence of LVH. 
Table 3 Logistic regression of the occurence of LVH WITHOUT repolarization abnormalities and 
the study variables. Table lists the estimate coefficient and the p-valueofthe Wald 
Où-square (n=1250) 
Variables Estimated Wald 
Coefficient Chi-square 
Male gender 0.14 < 0.01 
Age > 65 years 0.10 0.09 
Systolic BP > 160 mm Hg 0.20 < 0.01 
Diastolic BP > 105 mm Hg 0.06 0.06 
A logistic regression analysis showed that the following parameters had an influence 
on the occurrence of LVH without ST-T abnormalities (table 3): 
being male (p < 0.01) 
systolic blood pressure > 160 mmHg (ρ < 0.01) 
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Prevalence ofLVHby gender and systolic blood pressure. LVHwith and without 
repolarization abnormalities (n=1250) 
28% 
men women 
< 140 140-160 >160 <140 140-160 >160 
Systolic blood pressure (mm Hg) 
Figure 2 Prevalence ofLVH by gender and diastolic blood pressure. LVH with and without 
repolarization abnormalities (n=1250) 
26% women 
< 90 90-105 > 105 < 90 90-105 > 105 
Diastolic blood pressure (mm Hg) 
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There was an influence (not significant) of diastolic BP > 105 mmHg (ρ = 0.06) 
and age > 65 yrs (p = 0.09). The treatment status, duration of hypertension, smoking 
status, serumcholesterol. Body Mass Index and family history for cardio-vascular 
diseases did not have a significant influence on the occurrence of LVH. 
The occurrence of LVH WITH repolarization abnormalities was only significantly in­
fluenced by age > 65 yrs (p < 0.01). 
Discussion 
The data from this study in general practices correspond with those of studies in 
hypertension clinics and therefore make a contribution to the knowledge of hypertension 
in general practice. There have been few studies on the presence of ECG-LVH in 
hypertensive persons in general practice. The group of hypertensive patients is not 
a homogeneous group. A difference ought to be made between patients with little 
risk and patients with high risk of cardiovascular diseases in the short term. Some 
of the hypertensive patients were not being treated and some did not show signs 
of LVH on the ECG, but a remarkable proportion were aging, used antihypertensive 
drugs or had ECG-LVH. Up to now the estimation of risk seemed to be determined 
especially by the elevation of the blood pressure or the presence of other risk 
determinants. Within the group of hypertensive patients it is possible and probably 
necessary to differentiate. One out of five hypertensive persons had ECG-LVH and 
therefore a notable risk. Based on scientific data it must be accepted that treatment 
is very effective particularly in this group 1 6 1 7 1 8 1 Э . Although the use of the ECG to 
diagnose LVH has its limitations 2 0 , the ECG for detection of LVH in hypertension, 
especially in large population studies, is not as unreliable as some may think 2 1 . The 
sensitivity of ECG criteria for LVH has a range from 15% to 5 7 % and the specificity, 
with the echocardiogram as a 'golden standard', ranges from 8 6 % to 93%. The echo­
cardiogram, however, has a limited sensitivity (57%) for LVH when mild left ventricular 
hypertrophy is concerned2 2. In general practice studies and in large longitudinal popula­
tion studies the prevalence of mild LVH has been found to be higher than in clinical 
studies, where the prevalence of moderate and severe LVH is higher than in general 
practice. Furthermore, the ECG is more easily performed in general practice, while 
the use of an echocardiogram means the patient must be referred to a specialist. 
Regression of LVH is possible by means of improved treatment. For that purpose 
it is desirable to trace high-risk groups, in whom the development of LVH is more 
likely than in persons without a high risk. From the present study it can be concluded 
that LVH occurs more often in men, in persons > 65 years of age, and in patients 
with a less than optimally regulated blood pressure (both systolic and diastolic). 
Because there is a relation between age, gender, blood pressure and the occurrence 
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of LVH, improved blood pressure treatment could influence the risk of cardiovascular 
diseases. This risk needs to be studied in the population of general practice. The (cross-
sectional) data presented here are from a baseline measurement of a longitudinal 
study. Later on the effect of blood pressure treatment will be analyzed for the 
development or regression of ECG-LVH. 
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Introduction 
Prospective studies have shown that left ventricular hypertrophy (LVH) as assessed 
by electrocardiogram (ECG) is an independent risk factor for cardiovascular morbid-
ity and mortality in hypertensive patients.123 It was shown that LVH is the single 
most important predictor of both total and fatal coronary heart disease (CHD).45 Of 
patients with ECG-LVH, manifested by repolarization abnormality as well as 
increased voltage, 3 3 % of men and 21 % of women had died within 5 years. When 
evidence of LVH disappeared, the risk of all-cause, cardiovascular and CHD 
mortality was substantially reduced.6 Rigorous antihypertensive therapy is sug-
gested to prevent or diminish the development of LVH, thus improving the patients 
prognosis.7 8 9 To achieve successful regression of LVH, strenuous follow-up is 
essential.101112131416 Although echocardiography is more sensitive than electrocar-
diography for detecting LVH, ECG remains of value for an easy, inexpensive, and 
quick screening of large population studies.16171819 Previous results of our study 
showed that the prevalence of ECG-LVH in hypertensives treated in general 
practice was 21 %.20 The reproducibility of ECG criteria for LVH in our study was 
good.21 The aim of this study is to measure the time course of blood pressure and 
LVH in hypertensive patients in general practice and to assess the influence of 
special care treatment and blood pressure changes on LVH. 
Methods 
All patients diagnosed as hypertensive (N = 1803) in 16 general practices (22 GPs 
with 51,000 patients in and around Nijmegen, The Netherlands) were considered 
for the study. The patients had been detected by means of case-finding. After 
informed consent they were included in the study. Patients under treatment in the 
hospital were excluded. The practices were randomised into a special care (SC) and 
an usual care (UC) group. The SC practices used a computer-assisted hypertension 
care system (monthly computer feed-back on treatment and follow-up results and 
regular meetings of the participating general practitioners) in order to improve 
hypertension treatment.22 Feed back was targeted at the treatment objective of a 
diastolic blood pressure < 90 mmHg, with special attention to patients with LVH. 
The UC practices prescribed the in their view best antihypertensive treatment. 
At baseline measurement (T1 ) the following variables were measured: age, gender, 
Body Mass Index (BMI = kg/m2), blood pressure, ECG, total serum cholesterol, 
smoking habits, family history, duration of hypertension treatment and cardio-
vascular comorbidity. The measurements were made in a standardized way by two 
practice nurses trained especially for this study. After a follow-up of two years the 
same variables were registered again in a final measurement (T2). 
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Criteria 
1. BLOOD PRESSURE. 
Blood pressure was measured two times, at an interval of five minutes, in 
sitting position after five minutes of rest, using a digital, semi-automated 
sphygmomanometer with microphone ( Yamasu YSE-320)." The disappearance 
of the Korotkoff sounds (fase V) defined the diastolic blood pressure (DBP). The 
means of the two systolic blood pressure (SBP) values and the two DBP values 
were used for analysis. 
2. ELECTROCARDIOGRAM. 
The ECG was made by means of a Marquette electrocardiograph (MAC PC). 
The Marquette 12 SL Analysis Program provides a number matrix of leads and 
amplitudes. 
To describe the prevalence of LVH and the reclassification rate (see Statistics) 
the dimension of LVH was measured by computer in accordance with the 
Minnesota Code (MC).2425 There are two categories of LVH: LVH based only 
on voltage criteria (high QRS voltages without ST-T abnormalities - MC 3 . 1 , 
3.3 without 4.1 - 4.3 or 5.1 - 5.3) and LVH based on voltage criteria together 
with repolarization abnormalities (high QRS voltages with ST-T abnormalities -
MC 3 . 1 , 3.3 with 4.1 - 4.3 or 5.1 - 5.3). 
To measure changes in LVH voltages we used the voltage criterion according 
to Sokolow-Lyon (SL): S/V1 + the greater of R/V5 or R/V6.26 These changes 
in SL-voltages are used in the analysis of time course of blood pressure and 
treatment. 
Patients with intraventricular conduction disturbances ( WPW-pattern, complete 
left or right bundle branch block and ventricular block) and myocardial infarc-
tion were excluded, as it is difficult to assess the presence or absence of LVH 
in these patients. 
3. SERUM CHOLESTEROL 
Total serum cholesterol was measured on the same day of sampling at the 
central chemical laboratory of the Nijmegen Academic Hospital. 
4. QUESTIONNAIRE 
In a questionnaire patients were asked for cigarette smoking, positive family 
history (occurrence of myocardial infarction, cerebro vascular disease, hyper-
tension or diabetes in the first degree at an age < 55 years) and cardiovascular 
comorbidity (myocardial infarction, cerebro vascular disease or diabetes 
mellitus). 
5. DURATION HYPERTENSION TREATMENT 
From the patient file in general practice duration of hypertension-treatment was 
registrated. 
First, the change of LVH and blood pressure level were analysed in relation to the 
treatment group (SC vs UC). 
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Secondly, in an observational way, we compared the results in different subgroups. 
All patients were divided in four blood pressure groups composed on changes in 
blood pressure levels from T1 to T2. Two subgroups without change of an initial 
level; the first on a low level ( < 160/90 at T1 and T2), the second on a high level 
( > 160/90 at T1 and T2). Another subgroup with a change to a higher level ( < 
160/90 at T1 and £ 160/90 at T2) and the last subgroup with a change to a lower 
level ( à 160/90 at T1 and < 160/90 at T2). 
Statistical analysis 
Results of blood pressure and voltage measurements are presented as mean values 
with 95% confidence intervals (CI). Statistical significance between paired 
measurements is determined by means of a Student t test. Changes in the 
occurrence of LVH according to the Minnesota Code from T1 to T2 are presented 
in a Reclassification Rate (ReclRate), defined as the number of patients with 
regression of LVH minus the number of patients with progression of LVH divided 
by the total number of patients.21 Statistical significance of the ReclRate has been 
made by means of a McNemar test for symmetry.27 
By means of a multi level analysis the hypothesis was tested whether there was 
a practice dependent influence on the regression of LVH.28 If there is no influence 
a multivariate analysis is allowed. In a multivariate analysis the influence of socio-
demographic variables, clinical variables and riskf actors for cardiovascular diseases, 
on changes in SL-voltages from T1 to T2 (Diff-SL) was computed. The R-square 
value of the analysis represents the explained variance (%) of the examined 
dependent variable (the change in the SL-voltage from T1 to T2) on account of 
analysis variables. Parameters within the regression analysis were tested by means 
of a Student t test. 
Results 
In the 16 general practices 1803 patients had been diagnosed as hypertensive. 
From the 1803 patients 1376 (76%) entered the study. Hundred twenty eight 
patients were excluded on the basis of the criteria for exclusion and 299 patients 
refused to participate in the study. Of the 385 patients dropped out during the 
study the reason was: refusal of further participation (55%), on initiative of the 
general practitioner (15%), referai to hospital (11%) or loss from follow-up 
(removed or died; 19%). From 991 persons with a measurement at both T1 as T2 
120 patients were excluded because of intraventricular conduction disturbances or 
old myocardial infarction on the ECG. The population for final analysis consisted 
of 871 hypertensives. Five hundred eighty seven persons (67%) used 
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antihypertensive agents at T 1 . The characteristics of the analysed population 
(n = 871) did not differ significantly of that of the population at T1 (n = 1376) 
{table 1). 
Table 1 Baseline clinical characteristics of the hypertensives with only a baseline measure-
ment (n=1376) and the analysed population with both a baseline and final measur-
ement (n=871). 
η=871 Characteristics 
% Women 
Age (years) " 
range (years) 
BLOOD PRESSURE 
(mmHg) 
systolic * 
diastolic * 
Serum cholesterol ' 
Body Mass Index * 
Smokers (%) 
' (mmol/L) 
(kg/m2) 
FAMILY HISTORY (%) 
cardiovascular 
hypertension 
TREATMENT (%) 
no medication 
disease 
antihypertensive medication 
n=; 
62 
60 
18 
149 
87 
6.5 
28 
25 
3 
34 
28 
72 
L376 
± 12 
- 93 
± 21 
± 10 
±1.2 
± 4 
63 
58 
25 
148 
87 
6.4 
28 
26 
3 
36 
33 
67 
± и 
- 93 
± 20 
± 9 
±1.2 
± 4 
" Mean ± SD are given 
Results in the total group 
The initial mean BP was 148/87 and 2 1 % had LVH, on the basis of the high 
voltage criterion (18%) and additional repolarization abnormalities (3%). At the end 
of the study the mean BP was 149/87, with LVH present in 18% (14% according 
to the high voltage criterion; 4 % additional repolarization abnormalities). The 
ReclRate of LVH was 3.1 %. The initial mean SL voltage was 2607 /Λ/ and there 
was a decrease during the study of 42 μ\/. At T1 7 4 % had a SBP < 160 mmHg 
and 6 3 % had a DBP < 90 mmHg. At T2 these percentages were 73 and 6 1 . 
{table 2 and table 3). 
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Table 2 Prevalence of Left Ventricular Hypertrophy and blood pressure level at baseline (Tl) 
and final measurement (T2) in the total group and Special Care versus Usual Care 
group. Given are percentages (N). 
Total group SC UC 
(N=871) (N=372) (N=499) 
Tl 
T2 
Tl 
T2 
LVH-
LVH +-
LVH + + 
LVH-
LVH + -
LVH + + 
SBP < 160 
DBP < 90 
SBP < 160 
DBP < 90 
79 (687) 
18 (156) 
3(28) 
82 (714) 
14 (126) 
4 (31) 
74 (642) 
63 (545) 
73 (634) 
61 (534) 
77 (286) 
20 ( 75) 
3(11) 
80 (298) 
15 ( 57) 
5 (17) 
71 (264) 
64 (239) 
71 (265) 
65 (243) 
80 (401) 
16(81) 
3(17) 
83 (416) 
14 ( 69) 
3 (14) 
76 (378) 
61 (306) 
74 (364) 
58 (291) 
Legend: 
• SC: Special care group; 
• UC: Usual care group; 
• LVH -: LVH absent; 
• LVH +-: LVH based only on high voltage criteria without repolarization abnormalities; 
* LVH + + : LVH based on voltage criteria with repolarization abnormalities; 
•• SBP < 160: systolic blood pressure < 160 mmHg; 
• DBP < 90: diastolic blood pressure < 90 mmHg. 
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Results in the special care (SC) versus usual care (UC) group 
There were no significant differences between the two treatment groups (SC vs 
UC) in the initial blood pressure levels (148/86 vs 147/87), the change of blood 
pressure (SBP: 1.3 vs 1.6 mmHg; DBP: 0.3 vs 0.7 mmHg) and percentages < 160 
mmHg systolic (71 % at T1 and 71 % at T2 vs 7 6 % at T1 and 7 4 % at T2) and < 
90 mmHg diastolic (64% at T1 and 6 5 % at T2 vs 61 % at T1 and 5 8 % at T2). 
There were no differences in the prevalence of LVH at T1 (23%; 2 0 % on high 
voltages; 3% additional repolarization abnormalities vs 19%; 1 6 % on high 
voltages; 3% additional repolarization abnormalities) and atT2 (20% { 1 5 % + 5%} 
vs 17% { 1 4 % + 3%}). Likewise there was no difference on the regression of LVH 
on SL-voltages between SC and UC group (-57//V { 9 5 % CI -94 -20} vs. -30//V 
{ 9 5 % CI -64 4}) (table 2,3). 
In patients without LVH and in patients with LVH based only on voltage criteria 
there was no difference in blood pressure changes and SL voltage changes 
between SC and UC group. In patients with LVH based on voltage criteria together 
with repolarization abnormalities there was a (not significant) difference in blood 
pressure change between SC and UC group. The decrease in SBP in those patients 
was less in the SC group than in the UC group (5.7 vs 10.1 mmHg), while the 
decrease in DBP was greater in the SC (9.0 vs 1.2 mmHg). The decrease in SL 
voltages was less in those patients in the SC group (152 vs 364/yV) (table 3). 
Results in the various blood pressure subgroups 
Two subgroups consisted of hypertensives with constant blood pressure levels 
during the study period. One subgroup on a low level and another subgroup on a 
high level. The subgroup with a blood pressure < 160/90 at both T1 and T2 had 
a significant decrease of 44 μ V in SL voltage and a significant decrease in Reel Rate 
of 4.8%, while the prevalence of LVH at T1 was 13.2%. Table 4 lists the main 
results for these subgroups. The significant increase in SBP and DBP (16.0 and 9.8 
mmHg) in the subgroup with a blood pressure < 160/90 at T1 and > 160/90 at 
T2 coincided with an increase in LVH and a significant change in ReclRate of -5.6% 
(p = 0.02) (prevalence of LVH at T1 : 12.4%). The subgroup with a blood pressure 
change to a lower level ( > 160/90 at T1 and < 160/90 at T2) had a significant 
decrease of 141 //V SL voltage change and in this subgroup there was of course 
a significant decrease in both SBP and DBP (14.8 and 9.0 mmHg) with a not 
significant decrease in ReclRate for ECG-LVH of 4.8% (p = 0.10), while the preva­
lence of LVH at T1 was 27.3%. The subgroup with a blood pressure > 160/90 at 
both T1 and T2 had no significant change in SL voltage, but a significant decrease 
in ReclRate of 5.5% (prevalence of LVH at T 1 : 30.4%). 
Table 5 lists results on blood pressure at baseline, changes in Sokolow-Lyon 
voltages Oc/V), the prevalence of LVH at baseline and ReclRate in different SL 
voltage categories. The lowest SL category ( < 2000 μν) showed a significant 
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Table 5 Blood pressure at baseline, change in Sokolow-Lyon voltages foV), Left Ventricular 
Hypertrophy at baseline and Reclassification Rate in different Sokolow-Lyon voltage 
categories. 
SL categories 
< 2000 д 
2000 - 3000 μ\ 
3001 - 4000 /iV 
> 4000 μΥ 
Ν 
199 (23%) 
438 (50%) 
182(21%) 
52 ( 6%) 
ΒΡ-Τ1 
139/85 
147/86 
153/89 
165/88 
Difr SL (CI) 
75 
(40 ПО) 
-7 
(-40 26) 
-169 
(-230 -108) 
-342 
(-499 -185) 
LVH-Tl 
6 
9 
45 
100 
RecIRate 
0.5 
0.9 
8.2 * 
13.5 ** 
• BP-T1: blood pressure (mmHg) at T1 (SBP/DBP); 
• Diff SL: difference in SL voltage (//V) between T1 and T2, calculated as T2-T1 ; 
• LVH-T1: Left ventricular hypertrophy (%) at T1 according to the Minnesota code; 
• RecIRate: Reclassification Rate (%) of ECG-LVH. CI: 95% confidence intervals. 
• Statistical significance: * ρ < 0.05; ** ρ < 0.01. 
Table 6 Multivariate analysis of risk-variables on changes in SL-voltages from Tl to T2 (Diff 
SL). Influence of variables are presented as regression coefficients with Ρ values. 
Regression coefficients with a Ρ values < 0.1 are presented (N=871). 
Variables Regression Coefficient 
Age 
Gender 
BLOOD PRESSURE AT Tl 
SBP 
DBP 
Duration of hypertension treatment 
Body Mass Index 
Serum Cholesterol 
Smoking status 
Family history 
BLOOD PRESSURE CHANGE 
SBP 
DBP 
Cardiovascular comorbidity 
-3.8 
-90.1 
4.1 
3.9 
< 0.01 
< 0.01 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
< 0.01 
0.01 
NS 
• SBP: systolic blood pressure; DBP: diastolic blood pressure; 
•· SL: Sokolow-Lyon voltage value; 
• NS: ρ > 0.1 
*• Explained variance of the model: 9% 
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increase in SL voltage of 75 /yV (95% CI 40 110) with at baseline 6 % LVH 
according to the Minnesota code and a ReclRate of 0.5%. The highest SL 
categories showed a significant decrease in SL voltage. In the category 3001 -
4000//V a decrease of 169//V (95% CI 108 230) with LVH present in 4 5 % and 
a significant ReclRate of 8.2%, and in the category > 4000//V a decrease of 342 
μ4 (95% CI 185 499) with 100% LVH and a significant ReclRate of 13.5%. 
In a multi level analysis there was no practice dependent influence (results not 
shown). The explained variance of the multivariate analysis model was 9 % (table 
6). Decrease of SL-voltage is related to a change in SBP (p < 0.01) and to a 
change in DBP (p = 0.01). At the same time SL-voltage decrease seems to be 
found more in men (p < 0.01) and older people > 65 years (p < 0.01). 
Initial SBP and DBP, duration of hypertension treatment, Body Mass Index, serum 
cholesterol, smoking status, family history on cardiovascular diseases and 
cardiovascular comorbidity had no influence on LVH regression. 
Discussion 
This study analyzed the effects of a stringent supervised care for hypertension (SC) 
on the regression of LVH. It was not possible to demonstrate an effect from the 
special care: the changes in BP and LVH in the patients in the group of general 
practices with special care were comparable to the changes in the patients in the 
group practices delivering usual care. The overall prevalence of LVH in this general 
practice based study was 2 1 % , indicating that LVH is a frequent finding in an 
unselected general population of hypertensive patients. A net regression of LVH 
was observed in 3% of the cases, (7% regression and 4 % development). The 
prevalence of LVH was comparable to the MRFIT study and the Hypertension 
Detection and Follow-up Program (HDFP), but lower than that found in the Glasgow 
study - all studies using the same criteria applied in this study for L V H . 5 8 1 2 2 9 The 
change in BP ¡n this study was less and the extent of regression of LVH was lower 
than observed by others (MRFIT, HDFP and Glasgow study). 
Important In analyzing long term effects of intervention is the reliability of the core 
measurements - in this study BP and LVH. Both warrant comments. All BP 
measurements used in this study had been collected by two practice nurses. They 
have been specially trained, and their performance was monitored during the study 
period. They used the same automated sphygmomanometer. 
Echocardiography is the preferred diagnostic tool for LVH but ECG is regarded a 
valid alternative method. 9 1 5 1 7 1 8 For practical reasons - the screening of a large 
group of patients selected from general practice - the ECG method was preferred. 
ECG-established LVH is related to CV mortality, and ECG established regression of 
- 5 3 -
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LVH resulted in a decline of CV mortality.3 4 5 6 This study showed a correlation 
between BP regression and regression of LVH. But regression of LVH was recorded 
as well in patients with a stable unsatisfactory controlled BP. This rises the 
question what other factors may influence LVH and what the natural history of LVH 
is. It is important to gain more insight in this - particularly as LVH is such a 
common finding in patients with hypertension. 
It is important to take into account that changes in SL voltages (increase in the 
lowest SL categories and decrease in the highest SL categories) in this study 
suggest an effect of 'regression to the mean'. 
The most striking finding of this study was the poor effect of the intervention -
special and on-going support for the general practitioner - in gaining vigorous BP 
control. There are some possible explanations for this: first, the quality of treatment 
in the usual care group. The study design did not exclude any influence on the 
performance in this group. For ethical reasons the general practitioners in the usual 
care group knew the results of the ECG, without an explanation or advice as given 
in the special care group. The intention in the special care group was to focus on 
lowering BP (especially DBP) in patients with LVH and not to use specific 
medication, which is probably more important than blood pressure control only. 
This study shows that decrease of BP is important in the regression of LVH. 
The most probable explanation however will have been through the consensus pro-
cedure on diagnosis and treatment in hypertension and the Dutch College of 
General Practitioners' published standards in CV prevention and hypertension.3031 
These guidelines encourage general practitioners to obtain vigorous control of BP 
and to pay particular attention to follow-up care. 
Our study shows a relation between BP decrease (SBP < 160 mmHg and DBP < 
90 mmHg) and regression of LVH. Yet, in both groups a substantial number of 
patients had an unsatisfactory controlled BP which did not change, or worsened 
during the study (26% with a SBP > 160 mmHg and 37% with a DBP > 90 
mmHg). This may point to the very strict criteria applied for insufficient control ( S 
160/90 mmHg), but might be due as well to the study design: patients were 
recruited for this study who were already under treatment for some time. The BP 
value at the start of the study was not identical to the untreated value. This way 
the better part of the possible improvement could have been achieved before the 
study period, with little room for improvement during the study. 
In conclusion, LVH seems a frequently encountered, and prognostically relevant 
aspect of hypertension in general practice. The study showed that better control 
of BP was related to a regression of LVH. The study did not demonstrate treatment 
- 5 4 -
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benefits from a special care strategy for general practitioners; the overall changes 
in BP and in LVH were limited. Yet the fact the frequency of LVH and its regression 
under successful BP-treatment should stimulate general practitioners to make 
further progress in the treatment of hypertension. 
Further research in general practice with newly diagnosed hypertensive patients in 
prospective, trials with various medication could give us insight in ECG-LVH 
regression (possibly ECHO-controlled) and its influence on morbidity and mortality. 
- 5 5 -
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Introduction 
Left ventricular hypertrophy (LVH) is an independent risk factor for cardiovascular 
morbidity and mortality in hypertensive p a t i e n t s . 1 2 3 4 5 6 Antihypertensive therapy 
prevents or diminishes the development of LVH, improving the patients prognosis.7 
β s To achieve successful regression of LVH, strenuous follow-up is essential.1 0 1 1 
12 13 14 1Б 16 
Reports on which antihypertensive agents are the most effective in reducing LVH 
are not unequivocal. In both the Multiple Risk Factor Intervention Trial (MRFIT) and 
the Hypertension Detection and Follow-up Program (HDFP), blood pressure (BP) 
decrease with diuretics was associated with a reduction in incidence of LVH as 
assessed by electrocardiogram (ECG).8 1 2 In meta-analyses of mostly open, 
uncontrolled treatment studies it was hypothesized that angiotensin-converting 
enzyme (ACE) inhibitors are more effective than other first-line therapies in reducing 
LVH as assessed by echocardiogram.1 7 4 1 0 Fagard concluded that methodological 
problems of meta-analyses can be avoided by restricting the analysis to comparative 
studies in which patients are randomly assigned to two or more treatment groups. 
Such a meta-analysis suggests that the regression of left ventricular mass with the 
use of diuretics, ß-blockers, calcium antagonists or ACE inhibitors is not signifi-
cantly different from the effect of the other three classes combined. 18 
In the Treatment of Mild Hypertension Study (TOMHS) drug-treatment group 
differences are minimal, but there is a difference between the ECG and echocar-
diographic LVH regression.19 It is suggested that ECG may be measuring an import-
ant prognostic characteristic in hypertensive persons that is different from the 
measurement of LVH calculated from echocardiograms.20 
In general practice little is known about the relation of BP and LVH in an unselected 
hypertensive population. This study is part of a research project on the treatment 
of hypertensive patients in general practice, with special attention to LVH. The aim 
of this study is to assess in a population under treatment for hypertension in general 
practice the relation between the antihypertensive drugs used, BP and LVH. This 
includes both the relation at a given time and the change over time. 
Methods 
This study has an observational design, assessing the relation between Sokolow-
Lyon (SL)21 voltages for LVH, BP and antihypertensive agents used in hypertensive 
patients in general practice and the relation between changes in these parameters. 
All patients diagnosed as hypertensive in 16 general practices were considered for 
the study (n = 1803). The patients had been detected by means of case-finding. 
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Patients under treatment in the hospital had been excluded. At baseline (T1) the 
following variables had been measured: age, gender, BP, ECG and kind of 
treatment. After a follow-up of two years the same variables were registered again 
(T2). 
Criteria 
1. BLOOD PRESSURE. 
BP was measured two times, at an interval of five minutes, in sitting position 
after five minutes of rest, using a digital, automated sphygmomanometer with 
microphone (Yamasu YSE-320). The disappearance of the Korotkoff sounds 
(fase V) defined the diastolic BP (DBP). The means of the two systolic BP (SBP) 
values and the two diastolic BP values were used for analysis. 
2. ELECTROCARDIOGRAM. 
The ECG was made by means of a Marquette electrocardiograph (MAC PC). To 
describe the prevalence of LVH and the Reclassification Rate (see Statistics) the 
dimension of LVH was measured by computer in accordance with the Minnesota 
Code (MC).22 " T h e presence of LVH was based on voltage criteria with or 
without repolarization abnormalities (high QRS voltages with or without ST-T 
abnormalities - MC 3 . 1 , 3.3 with or without 4.1 - 4.3 or 5.1 - 5.3). 
To measure changes in LVH voltages we used the voltage criterion according to 
Sokolow-Lyon (SL): S/V1 + the greater of R/V5 or R/V6.21 These changes in SL-
voltages are used in the analysis of time course in relation to BP and drugtreat-
ment. 
Patients with intraventricular conduction disturbances (WPW-pattern, complete 
left or right bundle branch block and ventricular block) and myocardial infarction 
were excluded, as it is difficult to assess the presence or absence of ECG-LVH 
in these patients. 
3. KIND OF TREATMENT 
The kind of antihypertensive agent with the daily dose was registered. 
Analysis 
First a survey of the baseline clinical characteristics, with treatment status and a 
survey of BP, SL voltages and the prevalence of LVH in various antihypertensive 
medication subgroups is given. Secondly, the changes of SL-voltages and BP had 
been analyzed in various treatment subgroups, taking into account the change in 
treatment status during the study. 
Most of the patients could be divided in the following medication subgroups: 
1. Patients without antihypertensive medication at T1 and T2 
2. Patients using antihypertensive medication at T1 and T2 
- 6 1 -
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. Patients using diuretics at T1 and T2 
. Patients using ß-blockers at T1 and T2 
. Patients using diuretics and ß-blockers at T1 and T2 
. Patients using ACE-inhibitors at T1 and T2 
. Patients using diuretics and ACE-inhibitors at T1 and T2 
3. Patients without medication at T1 and using medication at T2 
. Patients without antihypertensive medication at T1 and using diuretics at T2 
. Patients without medication at T1 and using ß-blockers at T2 
. Patients without medication at T1 and using ACE-inhibitors at T2 
. Patients without medication at T1 and using diuretics and ß-blockers at T2 
. Patients without medication at T I and using diuretics and ACE-inhibitors at 
T2 
4. Patients using medication at T1 and without medication at T2 
. Patients using diuretics at T1 and no antihypertensive medication at T2 
. Patients using ß-blockers at T1 and no medication at T2 
. Patients using ACE-inhibitors at T1 and no medication at T2 
. Patients using diuretics and ß-blockers at T1 and no medication at T2 
. Patients using diuretics and ACE-inhibitors at T1 and no medication at T2 
Statistics 
Results of BP and quantitatively measured voltages according to the SL criteria are 
presented as mean values with 95% confidence intervals (CI). Statistical sig-
nificance between paired measurements is determined by means of a Student t test. 
Changes in the occurrence of LVH are qualitatively measured according to the 
Minnesota Code from T1 to T2 and are presented in a Reclassification Rate 
(ReclRate), defined as the number of patients with regression of LVH minus the 
number of patients with progression of LVH divided by the total number of 
patients.24 Statistical significance of the ReclRate has been made by means of a 
McNemar test for symmetry.25 
In a multivariate analysis the influence of sociodemographic variables (age and 
gender), clinical variables (baseline BP) and baseline treatment status, on baseline 
SL-voltages was computed. In a second multivariate analysis the influence of socio-
demographic variables (age and gender), clinical variables (BP change) and treat-
ment status, on changes in SL-voltages from T1 to T2 (Diff-SL) was computed. The 
R-square value of the analysis represents the explained variance (%) of the 
examined dependent variable (baseline SL-voltage and the change in the SL-voltage 
from T1 to T2) on account of analysis variables. Parameters within the regression 
analysis are tested by means of a Student t test. 
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Results 
In the 16 general practices 1803 patients had been diagnosed as hypertensive. 
From the 1803 patients 1376 (76%) entered the study. There was a drop-out 
during the study of 385 patients and 120 patients had been excluded because of 
intraventricular disturbances or signs of a previous myocardial infarction on the 
ECG. The population for analysis consisted of 871 hypertensives. Table 1 shows 
the characteristics of the population at baseline. Sixty seven percent (587) used 
antihypertensive agents at T 1 . 
Table 1 Baseline clinical characteristics of the population. 
Characteristics η = 8 7 1 
% Women 
Age (years) * 
range (years) 
BLOOD PRESSURE (MM HG) 
systolic * 
diastolic * 
LVH present (%) 
Sokolow-Lyon voltage (/iV) * 
TREATMENT (%) 
No medication 
Diuretics only 
ß-blockers only 
Diuretics and ß-blockers 
ACE-inhibitors only 
Diuretics and ACE-inhibitors 
Various medication 
* Mean ± SD are given 
As can be seen the subgroups were variable in size from 284 without medication 
to the smallest subgroup of 13 subjects on a combination of enalapril and a diuretic 
(table 2). The mean age of the subgroups ranged from 56 to 68 years. The BP level 
at T1 was also variable in the systolic values (from 129 in the enalapril-diuretic 
subgroup to 154 mmHg in the Captopril mono-therapy subgroup), whereas the 
diastolic values showed a less variable pattern (from 82 to 88 mmHg). The voltage 
according to SL showed quite a substantial dispersion from 2241 to 2902 μΜ 
(about 2 3 % difference). The presence of LVH according to the MC appeared to vary 
from 11 % in the subgroup with thiazides and related agents combined with a 
potassium sparing diuretic to 3 3 % in the (small) subgroup with Captopril combined 
63 
58 
25-93 
148 
87 
21.1 
2607 
33 
15 
15 
13 
6 
5 
13 
± 11 
± 20 
± 9 
± 828 
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with a diuretic. Finally, in the table an impression of the mean dose is given to 
present an idea of the treatment policy of the participating general practitioners. 
Hundred thirteen patients (13%) used various medication (among others centrally 
acting a2-agonists {n = 13}, centrally acting agents with diuretic {n = 18}, ACE-
inhibitor with ß-blocker and diuretic {n = 15}, and calcium-antagonists with or 
without other agents {n = 14}). 
A multivariate analysis shows the influence of age (older), gender (male), SBP and 
the use of a diuretic at baseline on the extent of the SL-voltage at baseline 
(table 3). 
Table 3 Multivariate analysis of variables on baseline Sokolow-Lyon voltage. Influence of 
variables are presented as regression coefficients with Ρ values. Only regression 
coefficients with Ρ values < 0.05 are presented (N=871). 
Variables Regression Ρ value 
Coefficient 
Age -5.1 0.04 
Gender -449.0 < 0.01 
BASELINE BLOOD PRESSURE 
SBP 14.3 < 0.01 
DBP NS 
BASELINE TREATMENT 
No medication NS 
Diuretic only -204.7 0.03 
ß-blocker only NS 
Diuretic and ß-blocker NS 
ACE-inhibitor only NS 
ACE-inhibitor and diuretic NS 
Various medication NS 
• SBP: systolic blood pressure; 
• DBP: diastolic blood pressure; 
• NS: not significant (P > 0.05). 
• Explained variance of the model: 21 % 
The explained variance of the various variables on SL-voltage was 21 %. 
In the group of patients without antihypertensive medication at T1 and T2 LVH was 
present in 18.4% {table 4). There was no change in SL-voltage and the ReclRate 
was 2.6%, indicating LVH at T2 was present in 15.8%. A remarkable finding was 
that in the group of patients using the same antihypertensive medication at T1 and 
T2, patients using diuretics at T1 and T2 had a significant increase in DBP of 3.3 
mmHg. Persons using ß-blockers at both times had a significant increase in SBP of 
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Table 7 Multivariate analysis of variables on changes in Sokolow-Lyon voltages from TI to 
T2. Influence of variables are presented as regression coefficients with Ρ values. 
Only Ρ values < 0.05 are presented (N=871). 
Variables Regression Ρ value 
Coefficient 
Age -2.7 0.03 
Gender NS 
BLOOD PRESSURE AT Tl 
SBP -2.4 < 0.01 
DBP NS 
BLOOD PRESSURE REGRESSION 
SBP 4.6 < 0.01 
DBP 3.5 0.02 
SL at baseline 0.1 < 0.01 
Body Mass Index NS 
Medication at Tl and T2 61.6 0.04 
Medication at Tl and no medication at T2 NS 
No medication at Tl and medication at T2 NS 
•· SBP: systolic blood pressure; 
• DBP: diastolic blood pressure; 
• NS: not significant Ρ > 0.05. 
*• Explained variance of the model: 15% 
6.7 mmHg and despite this increase a significant regression in LVH (ReclRate: 
7.0%), with a not significant change in SL-voltage (-72 //V with CI: -151 7). In 
patients using diuretics and ACE-inhibitors at T1 and T2 there was a significant 
decrease in SL-voltage of -201 (CI: -350 -52), without a significant regression in 
LVH (ReclRate: 7.1 % ) , despite an increase of both SBP and DBP (respectively 6.2 
and 3.7 mmHg). In patients without medication at T1 and using medication at T2 
it is notable that all ReclRates were positive (table 5). This regression of LVH ranges 
from 0 % in the patients without antihypertensive medication at T1 and using 
diuretics at T2 to a significant regression in LVH of 16.7% in patients without 
medication at T1 and using ß-blockers at T2. Patients starting ß-blockers during the 
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study had also a significant decrease in SL-voltage of -143 //V (CI: -280 -6). 
In patients using medication at T1 and without medication at T2 all ReclRates but 
one are negative, a development of LVH ranging from 0% (patients using diuretics 
and ß-blockers at T1 and no medication at T2, and patients using diuretics and 
ACE-inhibitors at T1 and no medication at T2) to - 1 1 . 1 % (patients using ACE-
inhibitors at T1 and no medication at T2). In patients using ß-blockers at T1 and no 
medication at T2 the ReclRate was 3.3% (table 6). 
In a multivariate analysis the explained variance of various variables on changes in 
SL-voltage was 15% (table 7). If the significant p-value is put on < 0.05 decrease 
of SL-voltage was related to age (> 65 years), the height of SBP at baseline, the 
decrease of SBP and DBP, the height of SL voltage at baseline and use of 
antihypertensive agents at T1 and T2. 
Discussion 
In this study the aim was to assess both in an open, retrospective, observational 
design, and in a prospective way, the influence of treatment on changes in SL-volt-
ages and regression of LVH in general practice. This study shows some important 
findings. In our study 33% of the hypertensive patients did not use antihypertensive 
medication at baseline, although 22% of them had ECG-LVH. The transversal part 
of the study shows an influence of age, gender (male), systolic blood pressure and 
the use of a diuretic at baseline on the extent of LVH at baseline. The prospective 
part demonstrates that subjects on ß-blockade throughout the whole study exhibit 
a significant regression in the prevalence of ECG-LVH. Along the same line patients 
without medication at T 1 , but on ß-blocker therapy on T2 display both a quanti-
tative decrease in SL-voltage and a qualitative decrease in the percentage with ECG-
LVH on MC criteria. There is an overall positive trend in LVH regression in patients 
starting medication during the study and a negative trend (progression of LVH) in 
those who stopped using antihypertensive medication. 
Although ECG-LVH is the most important risk factor for cardiovascular morbidity 
and mortality in hypertensive patients, it is not common in general practice to 
monitor hypertensive patients for the development or regression of LVH. Most 
studies on regression of ECG-LVH use a qualitative measurement. In the Hyperten-
sion Detection and Follow-up Program (HDFP)8, the International Prospective 
Primary Prevention Study in Hypertension (IPPPSH)"11 and the Multiple Risk Factor 
Intervention Trial (MRFIT)12 electrocardiographic changes were assessed in accord-
ance with the Minnesota code, in which LVH is present or not. The Veterans 
Administration t r ia l7 and the European Working Party on High Blood Pressure in the 
Elderly (EWPHE)28 use the Sokolow-Lyon voltage criterion for LVH in a qualitative 
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way. There are few studies using the SL-voltage criterion in a quantitative way, 
although it is more important to assess changes in LVH as a continuum in a quanti-
tative way, rather than to assess these changes in a qualitative way beyond a 
certain threshold. Dunn et al 14 showed a significant reduction in electrocar-
diographic voltages in 6 months with atenolol in 12 patients with previously 
untreated essential hypertension (SL-voltage decrease from 3470 to 2890 //V). 
Cruickshank et a l 1 3 have demonstrated a significant regression in SL voltage in 129 
previously treated hypertensive patients within 5.1 years with a treatment based 
on atenolol (SL-voltage decrease from 2750 to 2220 ^V) . 
There are some limitations in this study. This study was not a randomized, con-
trolled clinical trial. The period between starting medicamentous treatment, medica-
tion change or withdrawal and the baseline measurement is not known and may 
have influenced the results, but it is likely that BP and LVH are good reflections of 
longterm antihyper-tensive treatment. The fact that some subgroups are small is 
another limitation. 
Lowering the BP in hypertensive patients is an important factor in regression of 
LVH, but only about half of the cases of ECG-LVH regression may be related to 
lowering BP.27 
In this study the role of the BP change is rather weak. The study shows that there 
is an influence of BP lowering on the regression of LVH, but BP did not explain all 
changes in LVH. To achieve regression of LVH, treatment of hypertensive patients 
must begin early in the course of hypertension, and it has been suggested that 
specific drugs offer the best choice.9 This study is the first study in general practice 
with emphasis on LVH as a high risk in patients with hypertension. 
Further research in general practice with ECG-screening and (ECG or 
echocardiographical) monitoring on LVH in hypertensive patients could give us 
more insight in the development and regression of LVH, a prognostically relevant 
aspect of hypertension. 
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Introduction 
Illness and disease may influence the patients' health status, and quality of life has 
become an important aspect of medical care. In case of hypertension quality of life 
may be implicated in a special way. Hypertension is a by and large a-symptomatic 
condition that in itself will not influence the patients' quality of life unless chronic 
complications have become manifest. With the inherent need of screening (healthy) 
individuals and treating asymptomatic cases with drugs ("pro-active care" 1 ) , the 
quality of life of hypertensives is particularly under threat through two potential 
factors: the process of screening/labelling, and the adverse effects of intervention. 
The effects of screening/labelling on the perceived health status of healthy 
functioning individuals is contradictory: an increase in illness behaviour has been 
documented 2 but this could not be confirmed in three studies from general 
practice.3 4 5 Jachuck et al reported a high frequency of adverse effects of 
hypotensive drugs e, particularly when the reporting was based on the patients' 
next-of-kin. Discontinuing drug treatment did lead to a marked improvement in 
perceived health status 7. With the introduction of even more powerful hypotensive 
drugs, the consequences for the patients' quality of life will become even more 
important. There are indications that ACE-inhibitors, beta-blockers and Ca-
antagonists might be preferred above other drugs in terms of their effects on quality 
of life β but reports are not unequivocal. 9 1 0 1 1 1 2 1 3 
As a consequence, the measurement of health status has become an important 
issue in general practice. For general practice 'health status' has been operated in 
terms of the patients' ability to perform tasks and roles: 'functional status' 1 4. This 
is a generic, patient related quality, irrespective of specific diseases implicated 1 5, 
and various instruments have been introduced. Next to these generic instruments 
disease specific measurement scales have been developed. Bulpitt developed a 
questionnaire to evaluate the quality of life in hypertension, with emphasis on 
potential side effects of drug treatment. 1 β 1 7 1 8 1 9 2 0 Another study suggest that 
changes in quality of life must be interpreted with great care, unless the influence 
of the blood pressure situation in itself has been considered with instruments for 
measurements of well-being and subjective symptoms (Subjective Symptoms 
Assessment Profile) 2 1. 
This study was part of a survey on the treatment of hypertension, with particular 
attention to regression of left ventricular hypertrophy (LVH). 
The aim of the study was to assess the quality of life of patients with hypertension 
in relation to an intensive treatment regimen, and in relation to the clinical features 
cardiovascular (CV) risk factors, blood pressure (BP), LVH assessed by electro­
cardiography (ECG) and comorbidity. 
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Methods 
The study was a two year follow-up study in primary medical care and included 
hypertensive patients of 16 general practices in the catchment area of the 
department of general practice and social medicine, university of Nijmegen. 
RANDOMISATION 
The participating practices were randomised in two groups: an intervention group, 
and a control group. In the intervention group the general practitioner received 
special support to provide special care (SC) for hypertension 22: information of 
treatment (achieved blood pressure and compliance with follow-up care) was 
collected systematically and feeded back to the general practitioner. Regular audit 
meetings between the general practitioners were organised to discuss the quality 
of hypertension care. The general practitioners in the control group received no 
additional supervision and provided their usual care (UC). 
PATIENTS 
All patients under treatment for hypertension in the 16 practices were asked to 
participate in this study. Patients were informed of the study and asked for infor-
med consent. Those agreeing to participate were included in the study. Two 
research assistants - specially trained practice nurses - collected all the information 
used in the analysis. For each patient the following data were collected at the start 
(T1) and the end of the study (T2): sex and age (only at T1), cardiovascular risk 
factors (smoking history, family history on CV disease, serum cholesterol and body 
mass index {BMI}), blood pressure, medication used, questionnaire on quality of life 
and ECG. 
Blood pressure was measured two times with an interval of five minutes in a sitting 
position, using a digital semi-automated sphygmomanometer. The means of the two 
systolic (SBP) and of the two diastolic (DBP) pressures were used for analysis. 
Electrocardiography (ECG) was made by means of a Marquette electrocardiograph 
(MAC PC). Its programme provided information on LVH in accordance with the 
Minnesota Code (MC): 2 3 2 4 2 5 using voltage criteria with or without repolarization 
abnormalities. In the analysis, as far as LVH is concerned, patients with intraventri-
cular conduction disturbances and an old myocardial infarction had to be excluded. 
The quality of life was assessed using a questionnaire consisting of three parts: (1) 
information on hypertension treatment, follow-up, compliance, CV risk factors 
(smoking behaviour and family history) and comorbidity (myocardial infarction, 
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diabetes and cerebrovascular disease); (2) a Complaint Rate (CR) calculated from 
symptoms and side-effects (part of a validated Dutch translation 7 of the Bulpitt 
questionnaire): 36 questions on the perceived quality of life and experienced 
frequently encountered adverse effects of hypotensive drugs. The rate is analyzed 
as a percentage of present symptoms or side-effects (24 possible complaints in 
women and 25 in men); (3) a Symptom Rating Test (SRT, a self rating scale of dis-
tress), enquiring after 37 items and assessing psychiatric morbidity with five dimen-
sions: anxiety, depression, somatic, cognitive and hostility. The test provides an 
overall score as well as separate subscalescores. Higher scores indicate adverse 
psychiatric effects 26. 
Cardiovascular risk factors are positive if a person smokes, the family history on CV 
disease is positive (first degree relatives with a myocardial infarction, cerebro 
vascular disease, hypertension or diabetes < 55 yrs), the serum cholesterol-level 
^ 7.0 mmol/L and the BMI S 27 kg/m2. 
Analysis 
Patients were allocated to the following groups for comparison: 
A. Care received (two groups): patients from SC practices (n = 322) vs. UC 
practices (n = 424). 
B. Blood pressure control on the basis of the blood pressure level at the start and 
the end of the study (four groups): patients with a blood pressure < 160/90 at 
the start and the end (n = 242) vs. > 160/90 at the start and the end (n = 228) 
vs. 2: 160/90 at the start and < 160/90 at the end (n = 139) vs. < 160/90 at 
the start and > 160/90 at the end (n = 137). 
C. LVH development/regression (four groups): patients without LVH throughout 
the study (n = 560) vs. patients developing LVH (n = 30) vs. patients with LVH 
throughout the study (n = 100) vs. patients where LVH disappeared during the 
study (n = 56). 
D. Cardiovascular risk factors (four groups): patients with one (n = 336), two 
(n = 182) or three (n = 24) additional risk factors vs. patients without additional 
risk factors (n = 204). 
E. Comorbidity (two groups): patients with cardiovascular comorbidity (n = 11 5) 
vs. patients without cardiovascular comorbidity (n = 631). 
F. Medication (four groups): patients using antihypertensive medication at the start 
and the end of the study (n = 385) vs. patients without antihypertensiva at the 
start and the end of the study (n = 201) vs. patients using antihypertensive 
medication at the start of the study and no medication at the end (n = 63) vs. 
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patients without using medication at the start and using antihypertensive 
medication at the end (n = 97). 
The perceived quality of life was analyzed on the basis of the second and the third 
part of the questionnaire (perceived symptoms or side-effects < Complaint Rate> 
and psychiatric effects <Symptom Rating Test>) . The average test scores and 
changes in these scores were compared between the above listed groups of 
patients. 
STATISTICAL ANALYSIS 
Statistical analysis was based on comparing group averages with the Student t-test 
if there was a normal distribution and with a Sign Rank Test if the distribution was 
not normal.27 
By means of a multi level analysis 2e the hypothesis was tested whether there was 
a practice dependent influence on the quality of life. If there is no such influence 
a multivariate analysis is allowed. By means of a multivariate analysis the influence 
was computed of some variables with a known risk for cardio-vascular diseases 
(age, gender, blood pressure, LVH, serum cholesterol, smoking status, BMI and 
family history), some time course parameters (changes in blood pressure, LVH and 
treatment) and cardiovascular comorbidity on the complaint rate at T1 and on 
changes in the complaint rate during the study (dependent variables). Within the 
analysis the variable SRT is included to see wether quality of life (CR) is influenced 
by the state of distress. 
The R-square value of the analysis represents the explained variance (%) of the 
examined dependent variables on account of the model variables. Parameters within 
the analysis are tested by means of a Student t test. 
Results 
Hundred twenty five patients (50 patients in the SC practices and 75 patients in the 
UC group) are excluded, because the questionnaire was not complete or not 
returned at all, thus 746 patients remaining in the study. 
The average Complaint Rate was 25.8% (95% CI 24.4 - 27.2) and the average 
Symptom Rating Test score was 10.9 (95% CI 10.1 - 11.7). The change during the 
study in CR was 0.2 and in SRT 0.7. Women reported a significant higher CR than 
men (29.3% {95% CI 26.6 - 32.0} vs. 20.4% {95% CI 17.5 - 23.3}). Women also 
reported a not significant higher SRT (11.2 vs. 9.9). Older patients ( > 65 year) had 
a not significant higher CR, although they had a lower SRT [table 1). The CR and 
SRT at T1 of patients receiving SC (25.7% and 10.9) did not differ from the score 
of patients receiving UC (26.2% and 10.5). There was no significant change in both 
scores (table 2). 
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Table 1 Complaint Rates (%) and Symptom Rating Test scores at baseline (Tl) by sex 
and age (95% Confidence Intervak). 
N Complaint 
Rate Tl 
Symptom Rating 
TestTl 
Total group 
Male 
< 45 yr 
45-65 yr 
> 65 yr 
Female 
< 45 yr 
45-65 yr 
> 65 yr 
746 
292 
36 
160 
96 
454 
39 
257 
158 
25.8 
(24.4 27.2) 
20.4 
(17.5 23.3) 
18.1 
(13.5 22.7) 
19.2 
(16.8 21.6) 
23.3 
(20.2 26.4) 
29.3 
(26.6 32.0) 
28.0 
(22.6 33.4) 
28.7 
(26.4 31.0) 
30.7 
(28.1 33.3) 
10.9 
(10.1 11.7) 
9.9 
(8.1 11.7) 
10.2 
(7.5 12.9) 
10.6 
(9.0 12.2) 
8.6 
(6.9 10.3) 
11.2 
(9.7 12.7) 
12.2 
(9.2 15.2) 
11.5 
(10.0 13.0) 
10.5 
(9.2 11.8) 
Table 2 Complaint Rates, Symptom Rating Test scores at baseline (Tl) and changes from Tl 
to T2 by treatment regimen (95% Confidence Intervals). 
Treatment regi- N Complaint Complaint 
men Rate Tl Rate T2-T1 
Special Care 
Usual Care 
Symptom 
Rating 
TestTl 
Symptom 
Rating 
Test T2-T1 
322 
424 
25.7 
(23.8 27.6) 
26.2 
(24.5 27.9) 
0.7 
(-0.8 2.2) 
-0.2 
(-1.5 1.1) 
10.9 
(9.7 12.1) 
10.5 
(9.5 11.5) 
0.7 
(-0.3 1.7) 
0.5 
(-0.3 1.3) 
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There was no difference between the CR of the four blood pressure groups: 26.1 % 
for patients with a stable BP < 160/90; 24.9% for patients with a stable BP 2: 
160/90; and 26.4% and 26.2% respectively for patients whose BP rose or lowered 
during the study period. Likewise there was no difference between the SRT and 
changes in CR and SRT in the different blood pressure groups. Patients developing 
LVH during the study period had a change in CR of 3.7%, significantly higher than 
patients who during the study period were without LVH (0.2%), had an unchanged 
LVH (-1.5%), or whose LVH regressed (0.8%) (results not shown). 
The CR and SRT at T1 of patients not using antihypertensive medication during the 
study (CR: 24.8%; SRT: 10.2) did not differ from the scores of patients, who 
received medication (CR: 27.6%; SRT: 10.3), stopped medication (CR: 27.8%; 
SRT: 11.4), or kept using medication during the study (CR: 25.6%; SRT: 10.6). 
There was no significant change in both scores. 
Persons with cardiovascular comorbidity had a slightly significant higher CR at T1 
(30.5% {95% CI 26.8 - 34.2}) than patients without cardiovascular comorbidity 
(25.3% {95% CI 23.9 - 26.7}). The presence of additional cardiovascular risk 
factors was not related to the CR: 2 6 . 1 % , 25.0% to 22.6% in the patients with 
one, two or three risk factors - and 27.6% in the patients without other risk factors 
(results not shown). 
In a multi level analysis there was no practice dependent influence on the quality 
of life (results not shown). The explained variance of the multivariate analysis model 
on the complaint rate at T1 was 32% and of the same model on change of CR was 
6% (table 3). In the model the SRT was the most important factor that had an 
influence on both the initial complaint rate and the change in the complaint rate. 
Without the SRT in the model the explained variance of the model on CR at T1 and 
change of the CR during the study should be 9% and 2%. Less important factors 
in the model influencing the initial CR were gender (women), age ( > 65 year), an 
initial systolic blood pressure ä 160 mmHg, an initial serum cholesterol > 7.0 
mmol/L, an initial BMI ä: 27 kg/m2 and a cerebrovascular disease in history. Less 
important factors in the model influencing the change of CR were an initial systolic 
blood pressure > 160 mmHg, a cerebrovascular disease in history, and diabetes 
mellitus. 
There was no significant change in specific main symptoms or side effects. A 
significant change in CR, like in the patients developing LVH during the study 
period, was not due to one or more specific symptoms. 
Likewise there was no significant change in the different subscales of the SRT 
(anxiety, depression, somatic, cognitive and hostility) during the study. 
Patients with the 10% highest SRT scores at T1 (n = 75) presented significantly 
higher complaint rates (43.9% {95% CI 39.9 - 47.9}) than patients with lower SRT 
scores (23.5% {95% CI 22.4 - 24.6}). 
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Table 3 Multivariate analysis of variables on the Complaint Rate at Tl and changes in 
Complaint Rate from Tl to T2. Influence of variables is presented as a 
regression coefficient with Ρ values. Only Ρ values < 0 1 are presented. 
Variables 
Age 
Gender 
SBP at Tl 
DBP at Tl 
SBP change 
DBP change 
LVH at Tl 
LVH change 
Complaint Rate Tl 
Regression Coefficient Ρ 
0 2 < 0 01 
7 6 < 0 01 
-0 1 004 
NS 
NS 
Complaint Rate change 
Regression Coefficient Ρ 
NS 
NS 
0 I 001 
NS 
NS 
NS 
NS 
NS 
Cardiovascular Risk factors 
Serum cholesterol 
Smoking status 
BMI 
Family history 
-Ol 0 03 
NS 
0 2 0 10 
NS 
NS 
NS 
NS 
NS 
Diabetes Mellitus 
Cerebrovascular disease 1 8 
Comorbidity: 
NS 
0 07 
1 4 
-3 2 
0 03 
< 0 01 
Citation 
store at 
Tl 
0 8 
NS 
< 0 01 0 2 
NS 
< 0 01 
• SBP/DBP at T1 systolic/diastohc blood pressure at T I , 
•· SBP/DBP change systolic/diastohc blood pressure change from T1 to T2, 
•· LVH at T1 LVH present at T1 on basis of the Minnesota Code, LVH change, change of LVH 
status during the study, 
•• BMI Body Mass Index, 
•· Medication use of antihypertensive drugs during the study. Comorbidity presence of 
diabetes mellitus, old myocardial infarction or cerebrovascular disease, NS ρ > 0 1 
Explained variance of the model on the Complaint Rate at T1 32% 
Explained variance of the model on change of the Complaint Rate from T1 to T2 6% 
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Discussion 
Hypertension involves individuals who to a large extent experience no symptoms 
and therefore will regard themselves as 'healthy'. The treatment of patients with 
asymptomatic hypertension is effective in terms of preventing major cardiovascular 
complications and extending life expectancy. A pro-active approach is essential in 
order to achieve such benefits, including diagnosis through case finding or 
screening, and protracted follow-up and, when indicated, treatment with potent 
drugs. There is genuine concern of the potentially harmful effects of diagnosis and 
follow-up treatment, and the quality of life of patients under treatment for 
hypertension therefore warrants special attention. This study was part of a larger 
project analyzing the effects of pro-active care on blood pressure control and 
hypertension related complications - particularly LVH - in patients already under 
treatment for hypertension in general practice. 
The average complaint rate of 26% was 4 - 8% higher than in other studies, the 
psychiatric morbidity rate (SRT) of 10.7 was a little higher, but comparable to that 
in other studies. 7 2° 
The average individual CR represents a high number of (hypertension treatment 
related) ill feelings and indicates an impact on the quality of life. However, the 
analysis did reveal few correlations of the quality of life with clinical features. 
Women, patients developing LVH, patients with cardiovascular comorbidity, 
patients with initial high systolic blood pressure levels and especially patients with 
a high distress score reported a poorer quality of life. Neither the pro-active 
treatment regimen, nor the presence of risk factors, nor the use of medication, nor 
the extent of BP control was related to the quality of life. The pro-active treatment 
regimen had no consequence for the quality of life; no increase but certainly no 
decrease. 
The Bulpitt questionnaire was developed as a disease specific instrument to 
measure quality of life. It takes into account the adverse effects of hypotensive 
drugs. The questionnaire enquires after a list of common symptoms, and this may 
imply that it measures, in part, the patients' tendency to perceive symptoms, or to 
complain. This way, its score will be influenced by the patients' distress (neuroti-
cism). 'Neuroticism' is an individuals' stable characteristic, unlikely to be sensitive 
to changes in health status or treatment. This may explain why differences in treat-
ment regimen or BP in this study were not reflected in a change of quality of life. 
In testing 'generic' health status instruments in general practice great care is given 
to the sensitivity to change, and there are increasing signs that some of these 
instruments in fact are able to monitor changes in the patients' condition. The 
finding of a poorer quality of life in patients developing LVH should be seen in this 
light as well. In itself does this finding make sense: LVH is related to a poor 
- 8 3 -
• Special care for hypertension in general practice: effects on objective and subjective health status 
prognosis, and therefore an important clinical feature. However, the quality of life 
of patients with an existing LVH was better than of patients developing it, and not 
different from patients without LVH. This, put together with the overall lack of 
differentiation in the quality of life measures makes it less probable that the 
development of LVH would have been picked-up by this quality of life instrument. 
In conclusion, this study reported a lower level of quality of life in patients with 
hypertension. But the study was unable to point out specific aspects of treatment 
or follow-up that particularly influenced quality of life. In this study a pro-active 
approach did not lead to a change in quality of life in comparison to usual care. 
There was no increase but certainly no decrease in quality of life. This emphasizes 
the need for further study to address this aspect. The use of a more generic, less 
from symptom perception dependent instrument should be recommended in this 
context. 
- 8 4 -
Pro-active care for hypertension: Effects on quality of life • 
References 
1. Hart JT. Reactive pro-active care: a crisis. Br J Gen Pract 1990; 40: 4-9. 
2. Haynes RB, Sackett DL, Taylor DW et al. Increased absenteism from work after detection and 
labeling of hypertensive patients. N Engl J Med 1978; 299: 741-44. 
3. Stone DH, Crisp AH. The effect of multiphasic screening on aspects of psychiatric status in 
middle age: results of a controlled trial in general practice. Int J Epidem 1978; 7: 331-4. 
4. Weel С van. Does labeling and treatment for hypertension increase illness behaviour? Fam Pract 
1985; 2: 147-50. 
5. Ree JW van. Systematic screening for and treatment of elevated risk factors is feasible in the 
general practice. Hart Bulletin 1981; 12: 69-76. 
6. Jachuck SJ, Brierley H, Jachuck S et al. The effects of hypotensive drugs on the quality of life. 
J Coll Gen Pract (Occas Pap) 1982; 32: 103-5. 
7. Kruijsdijk MCM van. Hypertensie opnieuw gemeten; een onderzoek in de huisartspraktijk naar 
de medicamenteuze behandeling van hypertensie. Dissertatie 1991 Nijmegen ISBN 90-9004157-5. 
8. Beto JA, Bansal VK. Quality of life in treatment of hypertension: a metaanalysis of clinical trials. 
Am J Hypertens 1992; 5: 125-33. 
9. Steiner SS, Friedhoff AJ, Wilson BL et al. Antihypertensive therapy and quality of life: a 
comparison of Atenolol, Captopril, Enalapril and Propranolol. J Hum Hypert 1990; 4: 217-25. 
10. Testa MA, Anderson RB, Nackley JF et al. Quality of life and antihypertensive therapy in men: 
a comparison of Captopril with Enalapril. N Engl J Med 1993; 328: 907-13. 
11. Croog SH, Levine S, Testa M et al. The effects of antihypertensive therapy on the quality of life. 
N Engl J Med 1986; 314: 1657-64. 
12. Levine S, Croog SH, Sudilovsky A, Testa M. Effects of antihypertensive medication on vitality 
and well-being. J Fam Pract 1987; 25: 357-63. 
13. Neaton JD, Grimm RH, Prineas RI et al. Treatment of mild hypertension study. JAMA 1993; 
270: 713-24. 
14. Scholten JHG, Weel С van. Report of an International Workshop of the WONCA Research and 
Classification Committee. In: Scholten JHG & van Weel С (eds) Functional Status Assessment 
in Family Practice. Lelystad: MediTekst 1992. 
15. Weel С van. Functional status in primary care: COOP/WONCA charts. Disability and 
Rehabilitation 1993; 15: 96-101. 
16. Bulpitt CJ, Dollery С Side-effects of hypotensive agents: evaluation by a self-administered 
questionnaire. Br Med J 1973; 3: 485-90. 
- 8 5 -
• Special care for hypertension іл general practice: effects on objective and subjective health status 
17. Bulpitt CJ, Dollery CT, Carne S. A symptom questionnaire for hypertensive patients. J Chron 
Dis 1974; 27: 309-23. 
18. Bulpitt CJ, Fletcher AE. The measurement of quality of life in hypertensive patients: a practical 
approach. BR J Clin Pharmacol 1990; 30: 353-64. 
19. Fletcher AE, Hunt S, Bulpitt CJ. Evaluation of quality of life in clinical trials of vascular disease. 
J Chronic Dis 1987; 40: 557-66. 
20. Fletcher AE, Bulpitt CJ, Hawkins CM et al. Quality of life on antihypertensive therapy: a 
randomized double-blind controlled trial of Captopril and atenolol. J Hypertens 1990; 8: 463-66. 
21. Dimenäs ES, Wiklund IK, Dahlöf CG, et al. Differences in the subjective well-being and 
symptoms of normotensives, borderline hypertensives and hypertensives. J Hypertens 1989; 7: 
885-90. 
22. Hoogen JPH van den, Ree JW van. Preventive cardiology in general practice: computer-assisted 
hypertension care. J Hum Hypert 1990; 4: 365-67. 
23. Prineas RJ, Crow RS, Blackburn H. The Minnesota Code Manual of electrocardiographic 
findings. Standards and procedures for measurement and classification. Boston: John Wright-PSG 
Inc. 1982;55-97. 
24. Blackburn H, Keys A, Simonson E et al. The electrocardiogram in population studies. Circulation 
1960;21:1160-1175. 
25. Hoogen JPH van den, Kruijsdijk MCM van, Ree JW van et al. Prevalence of left ventricular 
hypertrophy as assessed by electrocardiogram in treated hypertensive persons in general practice. 
J Hum Hypert 1993; 7: 473-7. 
26. Kellner R, Sheffield B. A self rating scale of distress. Psychol Med 1973; 3: 88-100. 
27. Siegel S. Nonparametric statistics for the behavioral sciences. McGraw-Hill Book Company INC. 
pp 75-83. 
28. Bryk AS, Raudenbush SW. Hierarchical linear models. Newbury Park, Ca: Sage 1992. 
- 86-
• 8 
GENERAL DISCUSSION AND CONCLUSIONS 
Main objective 
The main objective of this study is to analyze the effect of systematic hypertension 
treatment on the time course of blood pressure and LVH. The overall prevalence of 
LVH in this general practice based study is 21 %, indicating that LVH is a frequent 
finding in an unselected general population of previously treated hypertensive 
patients. A net regression of LVH is observed in 3% of the cases, (7% regression 
and 4 % development). It is not possible to demonstrate an effect from special care 
(SC): the changes in blood pressure (BP) and left ventricular hypertrophy (LVH) in 
patients in the group of general practitioners with SC are comparable to the 
changes in patients in the group of practices delivering usual care (UC). Before 
analyzing the effect of systematic hypertension treatment on the time course of 
blood pressure and LVH it is important to discuss two subquestions: the develop-
ment of a method for SC and the reproducibility of LVH assessed by electro-
cardiogram. 
Pilot study 
A subquestion in this study has been to develop an effective and feasible computer-
assisted hypertension monitoring system (HMS) in general practice. In a previous 
pilot study in 15 general practices follow-up and blood pressure results were 
measured. The practices have been randomized into a SC and an UC group. The SC 
practices have been using a computer-assisted hypertension care system (monthly 
computer feed-back on treatment and follow-up results and regular meetings of the 
participating general practitioners) in order to improve hypertension treatment. Feed 
back has been targeted at the treatment objective of a diastolic blood pressure < 
95 mmHg. The UC practices prescribed the in their view best antihypertensive 
treatment. 
In the SC group in 70% of the hypertensive patients the blood pressure target level 
of 95 mmHg has been reached. In the UC practices the blood pressure target level 
has been reached in 56%. In the SC practices 76% of the hypertensive patients 
have been under permanent surveillance in this period. In the UC group this per-
centage is 45. In an evaluation of the HMS at the end of the pilot study it appeared 
that the introduction of such a system is possible without major problems. The HMS 
has been considered to be effective (improved detection, follow-up and treatment 
of hypertensive patients) and it proved to be feasible. 
Reproducibility of LVH by electrocardiogram 
Another subquestion concerns the reproducibility of screening on LVH among 
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hypertensive persons in general practice. LVH can be measured by means of 
echocardiography or electrocardiography (ECG). In this study the use of ECG is 
chosen for various reasons. First, because in the literature there is a clear relation 
between ECG-LVH and cardiovascular morbidity and m o r t a l i t y . 1 2 3 4 Б Secondly, 
although the use of the ECG to diagnose LVH has its limitations, the ECG for 
detection of LVH in hypertension, especially in large population studies, is not as 
unreliable as some may think. e 7 e 9 T h e sensitivity of ECG criteria for LVH has a 
range from 15% to 5 7 % and the specificity, with the echocardiogram as a 'golden 
standard', ranges from 8 6 % to 9 3 % . 1 0 The echocardiogram, however, has a limited 
sensitivity (57%) for LVH when mild left ventricular hypertrophy is concerned.1 1 
Thirdly, there may be a difference between the ECG and echocardiographic LVH.1 2 
It is suggested that ECG may be measuring an important prognostic characteristic 
in hypertensive persons that is different from the measurement of LVH calculated 
from echocardiogram. 1 3 Another reason for using ECG is a practical one. Making 
an ECG in the practice or in an ECG laboratory is easier than echocardiography, 
requiring referral to a specialist till now. 
Before changes in LVH can be described, reproducibility of ECG-LVH ought to be 
known. A great deal of research has been done to develop new criteria for LVH 
with an acceptable sensitivity and reliability, but the diversity of these studies 
testifies to the difficulty of this problem. In our study we choose the criteria of the 
Minnesota code u 1 5 and the criteria according to Sokolow-Lyon , e , because of the 
low variation and the practical use. An important finding is that studies which use 
the Sokolow-Lyon and Minnesota criteria to detect ECG-LVH are not comparable 
with studies which use other criteria (Cornell and Gubner-Ungerleider criteria). 
After discussing two important subquestions of developing a method for SC and 
testing reproducibility of ECG-LVH now back to the main study. 
Prevalence of ECG-LVH 
The next important subquestion concerns the prevalence of LVH in hypertensive 
patients in general practice. The overall prevalence of LVH is 21 %. The prevalence 
of LVH is comparable to the MRFIT study 1 7 and the Hypertension Detection and 
Follow-up Program (HDFP) 1 8 1 9 2 0 , but lower than that found in the Glasgow study 2 1 
- all three studies used the same criteria for LVH as applied in our study. The 
change in BP in the present study is less and the extent of regression of LVH is 
lower than that observed by others (MRFIT, HDFP and Glasgow study). 
LVH occurs more often in men, in persons > 65 years of age, and in patients with 
a not optimally regulated blood pressure (both systolic and diastolic). 
The group of hypertensive patients is not a homogeneous group. A difference ought 
to be made between patients with low risk and patients with high risk of car­
diovascular diseases in the short term. Some of the hypertensive patients have not 
- 8 8 -
General discussion and conclusions • 
been treated and some did not show signs of LVH on the ECG, but a remarkable 
proportion is at old age, is using antihypertensive drugs or has ECG-LVH. Up to now 
the estimation of risk seems to be determined especially by the elevation of the 
blood pressure or the presence of other risk factors. Within the group of hyperten­
sive patients it is possible and probably necessary to differentiate. One out of five 
hypertensive persons has ECG-LVH and therefore a notable risk. Based on scientific 
data it has been accepted that treatment of hypertension is very effective 
particularly in this group. 2 2 2 3 2 4 2 S 
Regression of ECG-LVH 
In the main study within the HMS the feed back is targeted at the treatment objec­
tive of a diastolic blood pressure < 90 mmHg, with special attention to patients 
with LVH. In the main study, however, the HMS is not as effective as in the pilot 
study. There has been no difference during the study in reaching the blood pressure 
target level between SC and UC. A possible explanation for this discrepancy lies in 
the fact that in the pilot study the hypertensive patients were newly detected, while 
in our main study it concerned already known, previously treated hypertensive 
patients. 
The poor effect of the intervention - special and on-going support for the general 
practitioner in gaining vigorous BP control - requires comment. There are a number 
of possible explanations: first, the quality of treatment in the usual care group. The 
study design did not exclude any influence on the performance in this group. For 
ethical reasons the general practitioners in the usual care group knew the results 
of the ECG, without an explanation or advice as given in the special care group. The 
intention in the special care group has been to focus on lowering BP (especially 
DBP) in patients with LVH and it has not been the intention to change medication. 
It may well be that besides BP control other factors (specific antihypertensive 
treatment) play a role in the reduction of LVH. A second explanation may have been 
the introduction of a consensus procedure on diagnosis and treatment in hyperten­
sion and the introduction of the 'Hypertension Standard' of the Dutch College of 
General Practitioners' on cardiovascular prevention and hypertension. 2 β 2 7 These 
guidelines encourage general practitioners to obtain vigorous control of BP and to 
pay particular attention to follow-up care. 
Our study shows a relation between BP regression (SBP < 160 mmHg and DBP < 
90 mmHg) and regression of LVH. Yet, in both groups a substantial number of 
patients have an unsatisfactory controlled BP which did not change, or worsened 
during the study (26% with a SBP > 160 mmHg and 3 7 % with a DBP > 90 
mmHg). This may point to the very strict criteria applied for insufficient control ( > 
160/90 mmHg), but may be due to the study design as well: patients recruited for 
this study were already under treatment for some time. The BP value at the start 
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of the study is not identical to the untreated value. This way the better part of the 
possible improvement could have been achieved before the study period, with little 
room for further improvement during the study. 
Time course of BP and ECG-LVH in relation to hypertension treatment 
Antihypertensive therapy is suggested to prevent or diminish the development of 
LVH, improving the patients prognosis. 2 8 M Μ 3 1 3 2 э з Э 4 3 S э в 3 7 
Reports on which antihypertensive agents are the most effective in reducing LVH 
are not unequivocal. In our study we assess the relation between the 
antihypertensive drugs used, and blood pressure and LVH in hypertensive patients 
in general practice. In our study 3 3 % of the hypertensive patients are using no 
antihypertensive medication at baseline, although 2 2 % had ECG-LVH. Patients 
using ß-blockers throughout the study have a significant regression in ECG-LVH 
(qualitatively measured according to the Minnesota code). Patients without 
medication at baseline and starting ß-blockers during the study have a significant 
regression of ECG-LVH and a significant (quantitatively measured) regression in SL-
voltage. There is an overall positive trend in LVH regression in patients starting 
medication during the study and a negative trend (progression of LVH) in those who 
stopped antihypertensive medication. The study shows that there is an influence 
of blood pressure decrease on the regression of LVH, but BP did not explain all 
changes in LVH. Our study did not have a placebo controlled design and has 
therefore its limitations, but nevertheless strongly suggests an influence of one 
specific treatment (ß-blocker) on regression of LVH. 
Quality of life of hypertensive patients 
The last subquestion concerns the effect of special hypertension care in general 
practice on the quality of life of hypertensive patients in general practice. 
The mean complaint rate (CR) represents a high number of (hypertension treatment 
related) ill feelings and indicates an impact on the quality of life. The average com-
plaint rate of 26% in this study is 4 - 8% higher than in other studies, the 
psychiatric morbidity rate (symptom rating test: SRT) of 10.7 is a little higher, but 
comparable to that in other studies. 3B39The analysis did reveal few relations of the 
quality of life with clinical features. Women, patients developing LVH, patients with 
cardiovascular comorbidity, patients with initial high systolic blood pressure levels 
and especially patients with a high distress score (SRT) report a poorer quality of 
life. Neither the pro-active treatment regimen (SC), nor the presence of risk factors, 
nor the use of medication, nor the extent of BP control is related to the Initial quality 
of life or changes in it. The pro-active treatment regimen (SC) has no consequence 
for the quality of life. 
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Conclusions 
1. The overall prevalence of electrocardiographic left ventricular hypertrophy (ECG-
LVH) in this general practice based study is 21 %, indicating that LVH is a fre-
quent finding in an unselected general population of previously treated hyper-
tensive patients. 
2. It is not possible to demonstrate an effect from special care (SC) on blood 
pressure (BP) and LVH: the changes in BP and LVH in patients in the group of 
general practitioners with SC are comparable to the changes in patients in the 
group of practices delivering usual care. 
3. Patients using ß-blockers throughout the study or starting during the study have 
a significant regression in ECG-LVH. There is an overall positive trend in LVH 
regression in patients starting medication during the study and a negative trend 
(progression of LVH) in those stopping antihypertensive medication. 
4. The study shows that there is an influence of BP lowering on the regression of 
LVH, but BP explains not all changes in LVH. 
5. The criteria of the Minnesota code and the criteria according to Sokolow-Lyon 
in detecting ECG-LVH in hypertensive patients in general practice have a low 
variation and are of practical use. 
6. Studies which use the Sokolow-Lyon and Minnesota criteria to detect ECG-LVH 
are not comparable with studies which use other criteria (Cornell and Gubner-
Ungerleider criteria). 
7. Our study reports some lower level of quality of life in patients with hyperten-
sion than other comparable studies. 
8. This study did not demonstrate an effect from SC on quality of life. The study 
is unable to point out specific aspects of treatment or follow-up that particularly 
influenced quality of life. Women report a significant lower quality of life score 
than men. 
9. The most important factor having an influence on the quality of life in 
hypertensive patients is their state of distress. 
Recommendations 
1. Further research in general practice with high risk screening by means of an 
ECG and long-term monitoring by means of an ECG or echocardiogram of LVH 
in hypertensive patients could give us more insight in the development and 
regression of LVH, a prognostically relevant aspect of hypertension. 
2. Further research in general practice with newly diagnosed hypertensive patients 
in prospective trials with various medication could give us insight in ECG-LVH 
regression (possibly with echocardiography as a control) and its influence on 
morbidity and mortality. 
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• SUMMARY 
CHAPTER 1 contains the general introduction to this thesis. The incidence in the 
Continuous Morbidity Registration (CMR) was 4.9 per 1000 patients per year. A 
much larger group is under treatment (prevalence in the CMR was 58.9 per 
1000 patients per year). This chapter describes the most important randomised 
antihypertensive drug trials and hypertension studies in general practice. Further 
it discusses the prevention-paradox and the high-risk strategy. An important 
parameter in patients with high-risk of cardiovascular diseases is the presence of 
organ-damage, particularly left ventricular hypertrophy (LVH). The aim of this 
study is to analyze the effect of systematic hypertension treatment (special care) 
on objective and subjective health status of hypertensive patients in general 
practice, with special attention to hypertension treatment in hypertensive 
patients with LVH. It contributes to the high risk strategy of hypertension care 
and explores the effectiveness of supervised long term care. 
Subquestions related to the main aim are: 
. What is the effectiveness and feasibility of a computer-assisted hypertension 
monitoring system in general practice. 
. What is the reproducibility of screening on LVH among hypertensive persons 
in general practice and what are the optimal criteria. 
. What is the prevalence of LVH in hypertensive patients in general practice. 
. What is the effect of special hypertension care in general practice on the 
quality of life of hypertensive patients in general practice. 
Finally the design, the outline and some key aspects of the study are been 
discussed. 
CHAPTER 2 describes a pilot-study on follow-up and treatment of hypertensive 
patients in 15 general practices. From research projects in general practice on 
prevention of cardiovascular diseases it appears that preventive detection and 
intervention programmes can be effective. Longterm results on hypertension 
control are better when in practice a systematical follow-up exists with surveil-
lance of the hypertensive population. Based on research and international 
experience we developed the Nijmegen Hypertension Monitoring System. This 
computer assisted system has two components: a monthly feedback of treat-
ment results and a regular meeting of the participating GP's. These meetings 
have an audit character. We carried out an experiment in 7 study practices and 8 
normalcare practices. In view of the results we consider this hypertension 
monitoring system (improved detection, follow-up and treatment of hypertensive 
patients) to be effective and it proved to be feasible. The two components of 
the system (insight into treatment results in individual patients and in the whole 
hypertension population, insight into personal performance and the regular 
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group discussions about the results) were effective to stimulate the general prac-
titioners to assume an active attitude to the management of blood pressure 
follow-up and treatment. 
CHAPTER 3 descibes the reproducibility of electrocardiographic (ECG) criteria for 
left ventricular hypertrophy in hypertensive patients In general practice. Before 
changes in ECG voltages can be accepted as evidence for changes in LVH, the 
variability of ECG measurements must be known. Here we report on the results 
of variability of electrocardiographic single lead voltage parameters and (voltage) 
criteria for left ventricular hypertrophy in hypertensive patients in general 
practice. From 64 patients two electrocardiograms were recorded with an 
Interval of two minutes to measure the minute-to-minute variability. From 77 
patients two electrocardiograms were recorded with an interval of one week to 
measure the day-to-day variability. The coefficient of variation of voltage 
parameters for single leads ranged in the day-to-day group from 9.2% in R/l to 
4 2 % in T /V1 . The coefficient of variation for voltage combinations In this group 
ranged from 10.0% for the Sokolow-Lyon criteria to 13.7% for Gubner-Unger-
leider criteria. The reclassification percentages in the day-to-day group ranged 
from 0 % for Gubner-Ungerleider to 17% for Minnesota code criteria. A factor 
analysis showed that studies which use the Romhilt-Estes score, the Sokolow-
Lyon or the Minnesota criteria to detect ECG-LVH are not comparable with 
studies which use the Cornell or Gubner-Ungerleider criteria. 
CHAPTER 4 describes the prevalence of left ventricular hypertrophy as assessed 
by electrocardiogram in treated hypertensive persons in general practice. Many 
studies have paid attention to the prevalence of LVH as assessed by electro-
cardiogram In hypertensive patients. Patients with ECG-LVH show a considerably 
higher risk of cardiovascular morbidity and mortality than patients without ECG-
LVH. This paper describes the prevalence of LVH and the relation between LVH, 
age, gender and blood pressure. ECG, blood pressure, treatment, duration of 
hypertension, body mass index and total serum cholesterol were recorded. The 
dimension of LVH was computed in accordance with the Minnesota Code. One 
out of five hypertensive patients (21%) had LVH with or without repolarization 
abnormalities. LVH based on high QRS voltages only was found more often In 
men. LVH with repolarization abnormalities was more frequent in elderly pa-
tients. LVH was found more often in the highest systolic blood pressure catego-
ries (SBP > 160 mmHg) and in the highest diastolic blood pressure categories 
(DBP > 105 mmHg). A logistic regression analysis showed the influence on the 
occurrence of LVH of the following parameters: being male, age > 65 years, 
SBP > 160 mmHg and DBP > 105 mmHg. 
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CHAPTER 5 presents the results with regards to the regression of left ventricular 
hypertrophy in hypertensive patients in general practice. Left ventricular hyper-
trophy as assessed by electrocardiogram is an independent risk factor for 
cardiovascular morbidity and mortality in hypertensive patients. This study 
describes the time course of blood pressure and LVH in hypertensive patients in 
general practice and assesses the influence of special care treatment and blood 
pressure changes on LVH. Sixteen general practices were randomised into a 
special care and an usual care group. In the total group the initial mean BP was 
148/87 and 21 % had LVH. After two years the mean BP was 149/87, with LVH 
present in 18%. There were no significant differences between the two treat-
ment groups in the initial blood pressure levels, the change of blood pressure, 
the prevalence of LVH at baseline and regression of LVH on Sokolow-Lyon (SL) 
voltages. 
A multivariate analysis showed that decrease of SL voltage is related to a 
change in SBP and DBP and that SL voltage decrease seems to be found more in 
men and older people > 65 years. The study showed that better control of BP 
was related to a regression of LVH. The frequency of LVH and its regression 
under successful BP-treatment should stimulate general practitioners to make 
further progress in the treatment of hypertension. 
CHAPTER 6 presents the time course of blood pressure and left ventricular hyper-
trophy in relation to hypertension treatment in general practice. Antihypertensive 
therapy prevents or diminishes the development of LVH, improving the patients 
prognosis. In general practice little is known about the relation of blood pressure 
and LVH in an unselected hypertensive population. The aim of this study is to 
assess in a population under treatment for hypertension in general practice the 
relation between the antihypertensive drugs used, BP and LVH. This study has 
an observational design, assessing the relation between Sokolow-Lyon (SL) 
voltages for LVH assessed by electrocardiogram, BP and antihypertensive agents 
used in hypertensive patients in general practice and the relation between 
changes in these parameters. The transversal part of the study shows an influ-
ence of age, gender (male), systolic blood pressure and the use of a diuretic at 
baseline on the extent of LVH at baseline. The prospective part demonstrates 
that subjects on ß-blockade throughout the whole study exhibit a significant 
regression in the prevalence of ECG-LVH. Along the same line patients without 
medication at baseline, but on ß-blocker therapy at the end of the study display 
both a quantitative decrease in SL-voltage and a qualitative decrease in the 
percentage with ECG-LVH. There is an overall positive trend in LVH regression in 
patients starting medication during the study and a negative trend (progression 
of LVH) in those who stopped using antihypertensive medication. 
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CHAPTER 7 presents results of the pro-active care for hypertension and effects on 
Quality of Life. The quality of life of hypertensives is particularly under threat 
through the process of screening/labelling, and the adverse effects of Interven-
tion. The aim of this study was to assess the quality of life of patients wi th 
hypertension in relation to an intensive treatment regimen, and in relation to 
some clinical features (cardiovascular risk factors, blood pressure, left ventricular 
hypertrophy and comorbidity). The participating practices were randomised in an 
intervention group (special care), and a control group (usual care). The quality of 
life was assessed using a questionnaire consisting of a Complaint Rate (CR) 
calculated from symptoms and side-effects and a Symptom Rating Test (SRT: a 
self rating scale of distress). The overall CR was 25.8% (95% CI 24.4 - 27.2) 
and the average SRT score was 10.9 (95% CI 10.1 - 11.7). Women reported a 
significant higher CR than men (29.3% {95% CI 26.6 - 32.0} vs. 20.4% {95% 
CI 17.5 - 23.3}). Women also reported a not significant higher SRT (11.2 vs. 
9.9). Older patients (> 65 year) had a not significant higher CR, although they 
had a lower SRT. The CR and SRT at baseline of patients receiving special care 
(25.7% and 10.9) did not differ from the score of patients receiving usual care 
(26.2% and 10.5). There were no significant differences in changes of CR and 
SRT during the study period in both groups.In a multivariate model the SRT was 
the most important factor that had an influence on both the initial complaint rate 
and the change In the complaint rate. In conclusion, this study reported a lower 
level of quality of life in patients with hypertension than other studies. The study 
was unable to point out specific aspects of treatment or follow-up that particu-
larly influenced quality of life. This emphasizes the need for further study to 
address this aspect. The use of a more generic, less from symptom perception 
dependent instrument should be recommended in this context. 
CHAPTER 8, the general discussion and conclusions, discusses the meaning of 
this study on hypertension care in general practice, and conclusions and recom-
mendations are made. 
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• SAMENVATTING 
HOOFDSTUK 1 vormt de algemene inleiding van dit proefschrift. De incidentie van 
hypertensie in de Continue Morbiditeits Registratie (CMR) is 4,9 per 1000 
patiënten per jaar. Een veel grotere groep wordt behandeld (de prevalentie in de 
CMR was 58,9 per 1000 patiënten per jaar). Dit hoofdstuk beschrijft de belang-
rijkste gerandomiseerde antihypertensieve trials en hypertensie onderzoeken in 
de huisartspraktijk. Vervolgens wordt de preventie-paradox en de hoog-risico 
strategie besproken. Een belangrijke parameter bij patiënten met een hoog risico 
op hart-en vaatziekten is de aanwezigheid van orgaanschade, vooral linker 
ventrikel hypertrofie (LVH). Het doel van dit onderzoek is het effect te analyseren 
van systematische hypertensie behandeling (special care) op de objectieve en 
subjectieve gezondheidstoestand van hypertensiepatiënten in de huisartspraktijk, 
met speciale aandacht voor behandeling van hypertensiepatiënten met LVH. Het 
onderzoek geeft een bijdrage aan de hoog risico strategie van hypertensie 
behandeling en onderzoekt de effectiviteit van hypertensie bewaking op de 
langere termijn. 
Deelvraagstellingen bij dit hoofddoel zijn: 
. Wat is de effectiviteit en uitvoerbaarheid van een semi-geautomatiseerd 
hypertensie bewakingssysteem in de huisartspraktijk. 
. Wat is de reproduceerbaarheid van screening op LVH onder hypertensiepati-
ënten in de huisartspraktijk. 
. Hoe groot is de prevalentie van LVH onder hypertensiepatiënten in de huis-
artspraktijk. 
. Wat is het effect van special care op de kwaliteit van leven van hypertensie-
patiënten in de huisartspraktijk. 
Tenslotte worden de opzet en enkele belangrijke aspecten van dit onderzoek 
besproken. 
HOOFDSTUK 2 beschrijft een pilot onderzoek naar follow-up en behandeling van 
hypertensiepatiënten in 15 huisartspraktijken. Uit onderzoeksprojecten in de 
huisartspraktijk over preventie van hart-en vaatziekten blijkt dat preventieve 
opsporings- en interventieprogramma's effectief kunnen zijn. Resultaten van 
hypertensiecontroles op lange termijn zijn beter als er in de praktijk een systema-
tische follow-up bestaat met bewaking van de hypertensieve populatie. We 
ontwikkelden op basis van onderzoek en internationale ervaringen het Nijmeegse 
Hypertensie Monitoring Systeem. Dit semi-geautomatiseerde bewakingssysteem 
bestaat uit twee delen: een maandelijkse feedback van behandelingsresultaten 
naar de deelnemende huisartsen gecombineerd met regelmatig plaatsvindende 
vergaderingen. Deze vergaderingen hadden een toetsend karakter. We voerden 
een experiment uit in 7 'special care' praktijken en 8 'normal care' praktijken. Op 
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basis van de resultaten uit dit pilot onderzoek beschouwen we dit hypertensie 
bewakingssysteem (verbeterde opsporing, follow-up en behandeling van hyper-
tensiepatiënten) als effectief en uitvoerbaar. De twee pijlers van het systeem 
(inzicht in behandelingsresultaten op individuele patiënten en de hele hypertensie 
populatie, inzicht in eigen handelen en de onderlinge bijeenkomsten met discus-
sies over de resultaten) stimuleerden de huisartsen in het verkrijgen van een 
actieve houding wat betreft hypertensiemanagement. 
HOOFDSTUK 3 beschrijft de reproduceerbaarheid van electrocardiografische (ECG) 
criteria voor LVH van hypertensiepatiënten in de huisartspraktijk. Voordat 
veranderingen in ECG voltages kunnen worden geduid als bewijs voor verande-
ring in LVH, moet de variabiliteit van ECG metingen bekend zijn. Hier bespreken 
we de resultaten van de variabiliteit in voltage parameters van afzonderlijke ECG 
afleidingen en variabiliteit in criteria voor LVH. Van 64 patiënten zijn met een 
interval van twee minuten twee ECG's afgenomen om de variabiliteit op korte 
termijn (minuut groep) te meten. Van 77 patiënten zijn eveneens twee ECG's 
gemaakt met een interval van een week om de variabiliteit op langere termijn 
(week groep) te meten. De variatiecoefficiënt van voltage parameters in de 
afzonderlijke afleidingen varieerde in de 'week groep' van 9,2% in de R-top van 
afleiding I tot 42% in de T-top van afleiding V 1 . De variatiecoefficiënt van 
voltage combinaties in deze groep varieerde van 10,0% gebruik makend van de 
Sokolow-Lyon criteria tot 13,7% voor de Gubner-Ungerleider criteria. De reclas-
sificatie percentages in de 'week groep' varieerde van 0% voor Gubner-Ungerlei-
der criteria tot 17% voor de criteria volgens de Minnesota code. Een factor 
analyse liet zien dat onderzoeken die de Romhilt-Estes score, de Sokolow-Lyon 
of de Minnesota criteria gebruiken, niet vergeleken mogen worden met onderzoe-
ken die de Cornell of Gubner-Ungerleider criteria gebruiken. 
HOOFDSTUK 4 gaat in op de prevalentie van ECG-LVH in behandelde hypertensie-
patiënten in de huisartspraktijk. Er bestaan veel onderzoeken die aandacht 
hebben besteed aan deze prevalentie. Patiënten met ECG-LVH hebben een 
aanzienlijk hoger risico op cardiovasculaire morbiditeit en mortaliteit dan pati-
ënten zonder ECG-LVH. Dit hoofdstuk beschrijft de prevalentie van LVH en de 
relatie tussen LVH, leeftijd, geslacht en bloeddruk. Er hebben metingen plaatsge-
vonden wat betreft ECG, bloeddruk, body mass index en totaal serumcholeste-
rol. Tevens zijn de behandeling en de duur van het bestaan van hypertensie 
vastgelegd. De mate van LVH is berekend volgens de Minnesota Code. Een op 
de vijf hypertensiepatiënten (21%) had LVH met of zonder repolarisatie stoornis-
sen. LVH gebaseerd op louter hoge QRS voltages werd meer in mannen gevon-
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den. LVH met repolarisatie stoornissen kwam meer voor bij oudere patiënten. 
LVH werd meer gevonden bij patiënten in de hoogste systolische bloeddruk 
categorieën (SBD > 160 mmHg) en in de hoogste diastolische categorieën (DBD 
> 105 mmHg). Een logistische regressie analyse toonde de invloed aan van de 
volgende parameters op het voorkomen van LVH: mannelijk geslacht, leeftijd > 
65 jaar, SBD > 160 mmHg en DBD > 105 mmHg. 
HOOFDSTUK 5 laat de resultaten zien van regressie van LVH in hypertensiepati-
enten in de huisartspraktijk. ECG-LVH is een onafhankelijke risicofactor voor 
cardiovasculaire morbiditeit en mortaliteit in hypertensiepatiënten. Dit onderzoek 
beschrijft het beloop van bloeddruk en LVH en meet de invloed van 'special care' 
behandeling en bloeddrukveranderingen op LVH. Zestien huisartspraktijken zijn 
gerandomiseerd in een 'special care' en een 'usual care' groep. In de totale 
groep was de gemiddelde bloeddruk ten tijde van de basismeting 148/87 en 
2 1 % van de hypertensiepatiënten had LVH. Na twee jaar was de gemiddelde 
bloeddruk 149/87 en 18% had tijdens de eindmeting LVH. Er was geen signifi-
cant verschil tussen de twee behandelingsgroepen wat betreft het bloeddrukni-
veau in de basismeting, de bloeddrukverandering, de prevalentie van LVH in de 
basismeting en regressie van LVH in voltages gemeten met behulp van de Soko-
low-Lyon (SL) criteria. Een multivariate analyse gaf aan dat vermindering van SL 
voltages gerelateerd is aan een verandering in zowel systolische als diastolische 
bloeddruk en dat SL voltage vermindering meer leek voor te komen bij mannen 
en oudere mensen (> 65 jaar). Het onderzoek toonde aan dat betere bloeddruk-
controle in verband stond met een regressie van LVH. Het voorkomen van LVH 
en regressie ervan middels optimale bloeddrukbehandeling zou huisartsen moeten 
stimuleren extra aandacht te besteden aan de behandeling van hypertensie. 
HOOFDSTUK 6 beschrijft het beloop van bloeddruk en LVH, gerelateerd aan 
bloeddrukbehandeling in de huisartspraktijk. Antihypertensive therapie voorkomt 
of vermindert de ontwikkeling van LVH, daarmee de prognose van de patiënt 
verbeterend. Er is weinig bekend over de relatie tussen bloeddruk en LVH in een 
ongeselecteerde populatie als in de huisartspraktijk. Het doel van dit onderzoek 
was om de relatie vast te stellen tussen de gebruikte antihypertensieve medica-
tie, de bloeddruk en LVH in een populatie die in de huisartspraktijk behandeld 
wordt voor hypertensie. Dit onderzoek had een observationeel karakter, waarbij 
een relatie gezocht werd tussen SL voltages voor ECG-LVH, bloeddruk en de 
soort medicatie, en de relatie tussen veranderingen in deze parameters. Het 
transversele deel van dit onderzoek toonde een invloed van leeftijd, geslacht 
(mannelijk), systolische bloeddruk en gebruik van diuretica tijdens de basismeting 
op de mate van LVH ten tijde van de basismeting. Het prospectieve deel van het 
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onderzoek liet zien dat patiënten met ß-blokkers tijdens het gehele onderzoek een 
significante regressie van ECG-LVH vertoonden. Hetzelfde gold voor patiënten 
zonder antihypertensive medicatie tijdens de basismeting, maar ß-blokkers 
gebruikend tijdens de eindmeting. In deze groep vond zowel een kwantitatieve 
afname plaats wat betreft SL voltages, als een kwalitatieve afname in het voor-
komen van ECG-LVH. Er bestaat een positieve trend wat betreft LVH regressie 
bij patiënten die tijdens het onderzoek met antihypertensieve medicatie starten 
en een negatieve trend (toename van LVH) bij hen die tijdens het onderzoek 
stopten met medicatie. 
HOOFDSTUK 7 geeft de resultaten van een pro-actieve behandeling van hyperten-
siepatiënten op de kwaliteit van leven. De 'quality of life' van hypertensiepati-
enten staat onder druk door het proces van screening en/of labeling en de 
ongewenste effecten van behandeling. Het doel van dit onderzoek was de 
kwaliteit van leven van hypertensiepatiënten te meten in relatie met een meer 
intensieve behandeling en in relatie met enkele klinische kenmerken (cardiovas-
culaire risicofactoren, bloeddruk, LVH en comorbiditeit). De deelnemende 
praktijken waren verdeeld in een interventie groep (special care) en een controle 
groep (usual care). De kwaliteit van leven is gemeten met behulp van een 
vragenlijst bestaande uit een klachtenscore (CR: complaint reate), berekend aan 
de hand van symptomen en bijwerkingen, en een 'Symptom Rating Test' (SRT: 
een schaal voor 'distress'). De 'overall' CR was 25,8% (95% Cl 24,4% -
27,2%) en de gemiddelde SRT score was 10,9 (95% Cl 10,1 - 11,7). Vrouwen 
scoorden significant hoger wat betreft de CR score dan mannen (resp. 29,3% 
{95% Cl 26 ,6% - 32,0%} en 20,4% {95% Cl 17,5% - 23,3%}). Vrouwen 
hadden tevens een niet significante hogere score op de SRT score dan mannen 
(resp. 11,2 en 9,9). Oudere patiënten ( > 65 jaar) hadden een niet significant 
hogere score in CR, hoewel ze een lagere SRT hadden. De CR en SRT ten tijde 
van de basismeting van patiënten in de 'special care' groep (25,7% en 10,9) 
verschilden niet van de scores van patiënten die 'usual care' ontvingen (26,2% 
en 10,5). Evenmin waren er significante verschillen in veranderingen van CR en 
SRT gedurende het onderzoek in beide groepen. In een multivariate analyse was 
de SRT score de belangrijkste factor die van invloed was op zowel de hoogte 
van de initiële CR als op de verandering van CR tijdens het onderzoek. Tenslotte 
werd in dit onderzoek een lagere score gevonden wat betreft kwaliteit van leven 
van hypertensiepatiënten dan in andere onderzoeken. Het onderzoek kon geen 
specifieke kenmerken van behandeling of follow-up traceren die van bijzondere 
invloed waren op de kwaliteit van leven. Dit gegeven benadrukt de behoefte aan 
verder onderzoek op dit terrein. Het gebruik van een meer algemeen, minder van 
symptoomperceptie afhankelijk meetinstrument zou in deze context aanbevolen 
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kunnen worden. 
HOOFDSTUK 8, de algemene beschouwing en conclusies, bespreekt de betekenis 
van dit onderzoek op hypertensie behandeling in de huisartspraktijk, trekt enkele 
conclusies en geeft enkele aanbevelingen aangaande dit onderwerp. 
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omdat ik vond dat het gezin er niet onder zou mogen lijden, kan ik er toch niet 
omheen. Bedankt! 
Astrid weet er nog niets van, want zij vertoefde vaak in dromenland. 
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Jos P.H. van den Hoogen werd geboren op 26 juni 1953 te Nijmegen. Na het 
behalen van zijn Atheneum-B diploma heeft hij zijn dienstplicht vervuld en 
studeerde geneeskunde in Nijmegen. In 1984 werd de studie afgerond met het 
artsexamen, waarna hij in 1985 zijn huisartsenopleiding heeft gevolgd te 
Maastricht. Vanaf 1985 is hij werkzaam bij de vakgroep huisartsgeneeskunde te 
Nijmegen, waar hij betrokken is geweest in diverse onderzoeksprojecten. Vanaf 
1987 werkt hij part-time als huisarts te Wijchen, aanvankelijk in dienstverband 
en vanaf 1990 in associatie met P. de Winter en vanaf 1992 met B. van Drenth. 
Vanaf 1992 werkt hij als staflid preventie op het NHG. 
Hij is gehuwd met Ine Paans en is trotse vader van Astrid. 
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STELLINGEN 
1. Een op de vijf hypertensiepatiënten in de huisartsprak-
tijk heeft een electrocardiografisch vastgestelde linker 
ventrikel hypertrofie en loopt daardoor extra risico op 
hart- en vaatlijden (dit proefschrift). 
2. Voor het vaststellen van electrocardiografische linker 
ventrikel hypertrofie in de huisartspraktijk zijn de 
criteria volgens Sokolow-Lyon zeer wel bruikbaar. Ze 
worden reeds lang gebruikt, zijn redelijk betrouwbaar en 
zijn makkelijk uitvoerbaar (dit proefschrift). 
3. De kwaliteit van leven van hypertensiepatiënten in de 
huisartspraktijk wordt meer beïnvloed door hun score op 
psychisch onwelbevinden dan door symptomen, klachten of 
bijwerkingen van hypertensie(behandeling) (dit proef-
schrift) . 
4. Gezien de hoge specificiteit van een electrocardiogram 
voor het aantonen van linker ventrikel hypertrofie is het 
advies 'Bij duidelijke aanwijzingen voor LVH op het ECG 
valt te overwegen een echocardiogram te maken' op zijn 
minst twijfelachtig (Consensus Diagnostiek en Behandeling 
Hypertensie. Hart Bulletin oktober 1990; 21-5:148)· 
5. Subsidies voor wetenschappelijk onderzoek kunnen effici-
ënter en effectiever gebruikt worden indien een deel van 
te voren gereserveerd kan worden voor een degelijke 
voorbereiding van de subsidieaanvraag. 
6. In het kader van de hulpvraagverheldering bij patiënten 
is het voor de huisarts zinvol de Story te lezen en de '5 
uur-show' te bekijken. 
7. De bijsluiter van een medicament wordt toenemend meer 
gebruikt ter indekking van de fabrikant dan als informa-
tiemiddel voor de patiënt. 
β. Gezien de kinderaanwas van onderzoeker en assistentes kan 
het doen van wetenschappelijk onderzoek bestempeld worden 
als een vruchtbare aangelegenheid. 
9. Indien bij elke uitgebrachte stem 'airmiles' te verdienen 
zouden zijn, zou het opkomstpercentage van verkiezingen 
aanzienlijk toenemen. 
10. Gezien het feit dat de laatste stelling van een proef­
schrift vaak als eerste gelezen wordt, is het aan te 
bevelen hierin dan ook de belangrijkste boodschap op te 
nemen. 
Stellingen behorend bij het proefschrift van Jos van den 
Hoogen: Special care for hypertension in general practice: 
effects on objective and subjective health status. Nijmegen: 
Katholieke Universiteit Nijmegen, 22 september 1995. 



